Curriculum Vitae
Blood Products Advisory Committee
Adrian Michael Di Bisceglie
| NAME: | Adrian Michael Di Bisceglie |
| ADDRESS: | ---------------------- ---------------------- -------------------- |
| OFFICE: | Department of Internal Medicine Saint Louis University School of Medicine 1402 South Grand Boulevard St. Louis, Missouri 63104 Tel: (------------ Fax: (314) 577-8125 E-mail: dibiscam@slu.edu |
| DATE AND PLACE OF BIRTH: | ----------------- ----------------- |
| CITIZENSHIP: | ------ |
| MARITAL STATUS: | --------- |
| LANGUAGES: | English Afrikaans |
| EDUCATION: | |
| ---- | Bachelor of Medicine and Bachelor of Surgery (MB Bch), University of the Witwatersrand, Johannesburg, South Africa |
| ---- | Master of Medicine in Internal Medicine (M. Med), University of the Witwatersrand |
POSTGRADUATE TRAINING:
1978 Intern: Coronation Hospital, Johannesburg1980 (Jan Jun) Senior House Officer: ENT surgery, Johannesburg Hospital
1980-1981 Military Service
1981-1984 Registrar: Dept of Medicine, Baragwanath Hospital, Johannesburg
PRESENT POSITION:
1999 to date Chief of Hepatology, Division of Gastroenterology and Hepatology
PREVIOUS POSITIONS HELD:
1984-1985 Physician: Dept of Medicine, Baragwanath Hospital, Johannesburg
1985-1986 Guest Researcher: Liver Diseases Section, NIH, Bethesda, MD
1986-1988 Visiting Associate: LDS, NIDDK, NIH
1989-1991 Senior Investigator: LDS, NIDDK, NIH
1991-1994 Chief, Hepatitis Studies Section, NIDDK, NIH
1992-1994 Chief, Liver Diseases Section, NIDDK, NIH
1994-1999 Associate Chairman, Dept. of Internal Medicine, Saint Louis Univ. School of Medicine
1997-2004 Medical Director, American Liver Foundation
POSTGRADUATE DIPLOMAS etc:
1978 ECFMG
1982 Fellowship of South African College of Medicine [FCP (SA)]
1984 Registered with South African Medical and Dental Council as Specialist Physician.
1983 Visa Qualifying Examination (VQE)
1986 Master of Medicine in Internal Medicine (M. Med.) for dissertation "Detection of alpha foetoprotein messenger RNA in human hepatocellular carcinoma tissue".
1988 Federation Licensing Examination (FLEX)
1990 Fellow of the American College of Physicians
1990 Board Certified in Internal Medicine (re-certified in 2002)
1991 Board Certified in Gastroenterology (re-certified in 2002)
ACADEMIC APPOINTMENTS HELD:
1992-1994 Adjunct Associate Professor of Medicine at George Washington University
1994 Professor of Internal Medicine, Saint Louis University (Tenured 1996)
MEDICAL LICENCES HELD:
1988 Maryland ------------ (inactive)
1995 Missouri -------------
HONORS/AWARDS:
| 1974-1977 | Barlow Rand Undergraduate Scholarship |
| 1984 | James Gear Traveling Fellowship in Virology |
| 1984 | South African Gastroenterology Society Traveling Fellowship |
| 1984 | C.J. Adams Memorial Trust Traveling Fellowship |
| 1993 | Invited speaker 6th Annual Hyman J. Zimmerman lecture |
| 1996 | Honorary Member of the Argentinean Society of Hepatology |
| 1997 | Osler Award for best teacher given by Internal Medicine Residents |
| 1999 | Honorary Life Member of the South African Gastroenterology Society (SAGES) |
| 2000 | Stephen L. Winter, M.D. 16th Annual Memorial Hepatology Lectureship
Featured Speaker, Univ. of Illinois-Chicago, June 15, 2000 |
| 2001 | Named Award. American College of Physicians' Adrian M. Di Bisceglie Book Award given to a graduating medical student at Saint Louis University based upon performance in General Internal Medicine activities and on outstanding ethical and humanitarian qualities |
| 2002 | Robert L. Peters M.D. lecture on "Management of hepatocellular carcinoma", University of Southern California. |
| 2002 | Fiterman Foundation Clinical Research in Hepatology or Nutrition (Hugh R. Butt) Award |
| 2003 | Leon Schiff Clinical State of the Art lecture at 2003 Annual Meeting of the American Association for the Study of Liver Diseases on "Hepatocellular Carcinoma: Challenges and Opportunities" |
| 2005 | 11th Annual Leon Schiff lecture at University of Miami on "An Update of Hepatocellular Carcinoma" |
RESEARCH INTERESTS:
Viral hepatitis, particularly aspects of its treatment and natural history. Hepatocellular carcinoma, particularly its relationship to chronic viral hepatitis.
MEMBERSHIP OF PROFESSIONAL SOCIETIES:
American Association for the Study of Liver Diseases (AASLD)
International Society for Interferon Research (ISIR) 1985-1988
American Gastroenterological Association (AGA)
American College of Physicians (Fellow)
European Association for the Study of the Liver
International Association for the Study of the Liver
MISCELLANEOUS:
Organizer and moderator of NIH Combined Clinical Staff Conference on Hepatocellular Carcinoma, December 3rd 1986, NIH.
Organizer (together with Drs. E Tabor and RH Purcell) of a national conference on Hepatocellular Carcinoma in North America in Bethesda, September 26 27th 1990.
Organizer (together with Dr. Michael A. Gerber) of the AASLD Clinical Research Single Topic Conference on Hepatocellular Carcinoma, St. Louis, MO, March 27-29th 1998
Organizer (together with Dr Charles Rice) of the first AASLD Hepatitis Single Topic Conference on "New Therapeutic Strategies for Hepatitis C" in Chicago, June 15 and 16, 2001.
COMMITTEES:
International
EASL Expert Panel on Hepatocellular Carcinoma 2000
Organizing and Scientific Committee 10th International Symposium on Viral Hepatitis and Liver Disease, Atlanta 2000
National
AASLD Research Committee 1991-1994
AASLD Abstract Review Committee (Hepatitis) 1992
AASLD Abstract Selection Committee (Hepatitis C: natural history - Chair) 1995 to 2002
AASLD Abstract Selection Committee (Hepatitis C: Treatment) 2003 - to date (Chair 2004 - )
AASLD Public Policy Committee 2003 to date (Chair 2005 - )
AASLD Nominating Committee 2001 (elected by AASLD membership)
AASLD NIH Liaison Committee 2005 to date
Ad-hoc member FDA Advisory Board on Artificial Liver Support Devices in July, 1995
Ad-hoc member FDA Advisory Board on Biological Response Modifiers, July 1995
Expert Advisory Panel on Gastroenterology, United States Pharmacopoeial Convention 1995-2000 USP Revision Cycle. 1996 to 2000.
AASLD Clinical Research Committee 1996 to 2001 (Chair 1999 to 2001)
St. Louis Chapter of American Liver Foundation 1997 to date
AASLD Strategic Alliance Task Force 1997 - 1999
AASLD-IASL Finance Committee 1996-1998
Hepatitis Council, American Liver Foundation 1997 to date (Chair 1997 to 2004)
Ad-hoc Grant Reviewer for:
- Department of Veterans Affairs, Merit Review Board
- Louisiana Board of Regents
- NIDDK
- NIAID
- NIAAA
- AACTG
- Canadian Institutes of Health Research
- Canadian Liver Foundation
- Italian Ministry of Health
- National Blood Service (UK)
Ad-Hoc member of study sections:
- GMA-3 (2003)
- HPBB (2004)
Centers for Disease Control and Prevention to Update Recommendations for the Prevention and
Control of HCV Infection (Consultant), July 1998
EthicAd Steering Committee 1999 to 2000
Planning Committee for 2002 NIH Consensus Conference on Management of Hepatitis C
Hepatitis Advisory Committee (HAC) of the Adult AIDS Clinical Trial group (AACTG) (now the Hep RAC) 2003 to date
Virology Subcommittee of the AACTG 2004 to date
Planning Committee for 2004 NIH conference on Hepatocellular Carcinoma
Ad hoc member of the Board of Scientific Advisors of the Clinical Center of the National Institutes of Health, site visit 2004
Chairman, Hepatocellular Carcinoma group, NIDDK Liver Diseases Action Plan
Consultant to National Toxicology Program, DHHS, 11th Report on Carcinogens published in February 2005.
This report listed the hepatitis B virus and hepatitis C virus as known carcinogens for the first time.
Institutional
(National Institutes of Health:)
NIDDK Institutional Clinical Review Subcommittee (IRB) 1990-1994
(Saint Louis University Health Sciences Center:)
Graduate Medical Education Committee 1994 to 1999
Education Policy Committee 1994 to 1996
Documentation Practices Committee 1995 to 1998
Curriculum Management Committee 1996 to 1998
Curriculum Oversight Committee 1996 to 1999
Curriculum Design Committee Phase I/II (Co-Chair) 1995 to 1998
Continuing Medical Education Advisory Committee 1995
Cost Reduction Committee 1997 to 1998
SLUCare Facilities and Support Services Committee 1997 to 1998
Governing Board, Saint Louis University Hospital 1998 to 2000
Institutional Review Board 2001-2003
General Clinical Research Center Advisory Committee (GAC) 2001-
Member, Saint Louis University Cancer Center
Search Committee for Chairman of the Department of Pathology 2003/4
Review Committee for Department of Comparative Medicine (Chair) 2003/4
Search Committee for Associate Dean for Research 2004
Departmental
Executive Committee 1994 to 1999
Research Committee 1995 to date
Housestaff Evaluation Committee 1994 to 1999
Residency Education Committee 1995 to 1999
Search Committee for Director of Division of Hematology and Oncology (Chair) 1997 to 1998
Internal Medicine Quality Assurance Committee (Chair) 1997 to 1999
SoLUtions task force 2001 to 2002
TEACHING ACCOMPLISHMENTS:
Internal Medicine Residency Program Director 1995 to 1999
Co-Director Introduction to Clinical Medicine course for sophomore medical students 1996 to 1998
Co-Director of newly introduced Master Clinician course for senior medical students 1996
Co-Director Board Review Course for medicine residents 1995-1997
Director Gastrointestinal Module Course for Sophomore Medical Students 1998 to 1999
Director of newly introduced PORSS course (Patient-Oriented Research Seminar Series) 2003-2004
RESEARCH GRANTS:
Active:
Principal Investigator "NO1-DK-9-2324, Hepatitis C Clinical Trial Clinical Centers: Prevention of Cirrhosis, Hepatic Decompensation and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C" sponsored by NIH-NIDDK-98-4, $2,336,554, 1999-2004.
Co-Investigator "U01 DK60345-01 Response of HCV to therapy in African Americans" sponsored by NIDDK. 2001-2006, $1,560,868. John Tavis, P.I.
Co-Investigator N01-AI-25464. "A Phase I Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Chiron Corporation's HCV E1E2/Mf59 Vaccine Administered to Healthy HCV-Negative Adults". 2003-2004. Robert Belshe, P.I. $----------- for laboratory services to Dr Di Bisceglie.
Co_Investigator 5U01DK061718-03 "Hyperinsulinemia and pathogenesis of NASH (NASH-CRN)" Sponsored by NIDDK. 2004-2009. Brent A. Neuschwander-Tetri, P.I. Total direct costs $2,070,964
Completed:
Principal Investigator "R01DK5643501 Hepatitis C Viral Quasispecies within the Liver" sponsored by NIH-NIDDK, $1,649,514. 1999-2004.
Co-investigator "2-R01-DK46602-06, Treatment Study to Compare the Effects of Methotrexate plus UDCA vs. UDCA plus Placebo on the Course of Patients with Primary Biliary Cirrhosis (PBC)" sponsored by University of Texas-Southwestern, $--------, 1999-2004. Burton Combes, P.I.
Co-Investigator "2 R44 AI 46064-01 Phase II - Hepatitis C virus quantitation using the 3' NTR" sponsored by NIAID. 2001-2003. Total direct costs $677,994. Paul Olivo, P.I.
Principal Investigator "BIO6-002-004 Chemoprevention of hepatocellular carcinoma". US-Egypt Joint Science and Technology Board. 2002-2004. $-----------
Co-Investigator "1 U19 AI/DK 48220-01 ZA11 Functional analysis of HCV-B lymphocyte interactions" sponsored by NIDDK and NIAID. 2000-2004. Thomas Chambers, P.I.
Principal Investigator "SLU-2000. Saint Louis University Center of Excellence Award, $------, 2001-2004.
EDITORSHIPS:
Co editor (with Drs. E. Tabor and R.H. Purcell) of "Hepatocellular Carcinoma in North America", Portfolio Publishing.
Editorial Board "HEPATOLOGY" 1990-1991; 1995 to date
Associate Editor, "HEPATOLOGY" 1991 1995
Editor, "VIRAL HEPATITIS REVIEWS" 1995 to 2001
Guest Editor, "SEMINARS IN LIVER DISEASE", Vol. 19, Supplement 1, 1999
Editorial Board "TIMELY TOPICS IN MEDICINE - HEPATOLOGY" 1999 to date
Editorial Board "ARCHIVES OF GASTROENTEROLOGY," formerly "HELLENIC JOURNAL OF GASTROENTEROLOGY" 1999 to date
Medical Editor "PROGRESS - American Liver Foundation Newsletter" 1999 to 2004
Co-Editor (with Dr. Bruce Bacon) of "Liver Disease: Diagnosis and Management." Churchill Livingstone, New York, 1999.
Editorial Board for "MINERVA MEDICA," October 2000 to present.
Guest Editor, 'CLINICS IN LIVER DISEASE - LIVER TUMORS", Volume 5, Number 1. February 2001.
Editorial board "UPDATE IN HEPATOLOGY". 2001 to 2002.
Editorial board "LIVER TRANSPLANTATION" from 2005
Guest Editor (with Anna Linda Zignego) of "Update in Hepatology: HCV viral infection". 2002; UTET; Torino, Italy.
Editorial board "GUT". 1998-2004.
ORIGINAL PUBLICATIONS:
1. Phaeochromocytoma. Huddle KRL, Di Bisceglie AM and Feldman C. S Afr Med J 1982;61:286 288.
2. Myocardial infarction in an intensive care unit for blacks. Di Bisceglie AM, Miller MT, Blumsohn D. S Afr Med J 1982;61: 902 904.
3. Multiple myeloma and pernicious anaemia. Di Bisceglie AM, Hodkinson HJ. S Afr Med J 1982;62:535 536.
4. Continuous peritoneal dialysis in a developing population: Problems seen at Baragwanath Hospital. Di Bisceglie AM, DVA Mzamane. S Afr Med J 1983; 63:405 406.
5. Perforated duodenal ulcer associated with endoscopy resulting in pancreatic abscess. Di Bisceglie AM, Segal I, Ming RHC, Pantanowitz D, Elisseos C. S Afr Med J 1983; 63:461 462.
6. Primary sclerosing cholangitis. Di Bisceglie AM, Segal I, Hodkinson H, Posen J. Cent Afr J Med 1983;29:125 128.
7. Bacterial peritonitis due to an infected dialysis catheter. Di Bisceglie AM, Mzamane DVA. S Afr Med J 1983; 64:718 719.
8. Pitfalls in the diagnosis of gestational choriocarcinoma. Krige LP, Di Bisceglie AM. S Afr Med J 1984;65:26 27.
9. Pancreatic endocrine tumor presenting with obstructive jaundice. Di Bisceglie AM, Segal I, Mannell A, Posen J. Am J Gastroenterol 1984;79:43 44.
10. Benign extrinsic oesophageal dysphagia. Di Bisceglie AM, Segal I, Mirwis J. S Afr Med J 1985;67:219 221.
11. Transudative ascites with a high protein content. Di Bisceglie AM, Schamroth CL. S Afr Med J 1985;67:941 942.
12. Clinical and serological events accompanying changes in hepatitis B viral replication: case reports. Dusheiko GM, Bowyer S, Paterson AC, Song E, Di Bisceglie AM, Kew MC. Liver 1985;5:77 83.
13. Detection of markers of hepatitis B virus infection in urine of chronic carriers. Di Bisceglie AM, Dusheiko GM, Kew MC. J Med Virol 1985;16:337 341.
14. Smoking as a risk factor in hepatocellular carcinoma. Kew MC, Di Bisceglie AM, Paterson AC. Cancer 1985;56:2315 2317.
15. Recombinant leukocyte interferon treatment of chronic hepatitis B. Dusheiko GM, Di Bisceglie AM, Bowyer S, Sachs E, Ritchie M, Schoub B, Kew MC. Hepatology 1985;5:556 560.
16. The liver in biliary obstruction due to chronic pancreatitis. Di Bisceglie AM, Paterson AC and Segal I. Liver 1985;5:189 195.
17. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon; A pilot study. Sachs E, Di Bisceglie AM, Dusheiko GM, Song E, Lyons SF, Schoub BD, Kew MC. Br J Cancer 1985;52:105 109.
18. Hyponatraemia complicating treatment of myxoedema coma. Berkowitz I, Di Bisceglie AM. S Afr Med J 1986; 69:136 137.
19. Obstructive jaundice in South African Blacks. Di Bisceglie AM, Oettle GJ, Hodkinson HJ, Segal I. J Clin Gastroenterol 1986; 8:538 541.
20. Pityriasis Rotunda a cutaneous manifestation of hepatocellular carcinoma in South African blacks. Di Bisceglie AM, Hodkinson HJ, Berkowitz I, Kew MC. Arch Dermatol 1986;122:802 804.
21. Recombinant leucocyte interferon treatment of chronic hepatitis B: an analysis of two therapeutic trials. Dusheiko GM, Paterson AC, Pitcher L, Kassianides C, Di Bisceglie AM, Song E, Kew MC. J Hepatology 1986;3:5199 5207.
22. Prevalence of hepatitis B virus infection among black children in Soweto. Di Bisceglie AM, Kew MC, Dusheiko GM, Berger EL, Song E, Paterson AC, Hodkinson HJ. Br Med J 1986;292:1440 1442.
23. Detection of alpha foetoprotein messenger RNA in human hepatocellular carcinoma and hepatoblastoma tissue. Di Bisceglie AM, Dusheiko GM, Paterson AC, Alexander J, Shouval D, Lee C S, Beasley PR, Kew MC. Br J Cancer 1986:54:779 785.
24. Treatment of chronic non A, non B hepatitis with recombinant human alpha interferon: preliminary report. Hoofnagle JH, Mullen KD, Jones DB, Rustgi VK, Di Bisceglie AM, Peters M, Waggoner JG, Park Y, Jones EA. N Eng J Med 1986; 315:1575 1578.
25. Factors predisposing to central corneal ulceration in a developing population. Di Bisceglie AM, Carmichael TR. S Afr Med J 1987;71:769 770.
26. A randomized controlled trial of a 4 month course of recombinant human alpha interferon in patients with chronic type B hepatitis. Di Bisceglie AM, Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi VK, Avigan MI, Park Y, Waggoner JG, Jones EA. In, Schellekens H, Cantell K. Proceedings of the 1986 ISIR/TNO Meeting. 1987 Martinus Nijhoff. Dordrecht.
27. Hepatitis B virus DNA in liver of chronic carriers: correlation with serum markers and changes associated with loss of hepatitis B e antigen following anti viral therapy. Di Bisceglie AM, Waggoner JG, Hoofnagle JH. Gastroenterology 1987;93:1236 1241.
28. Therapy of chronic viral hepatitis: chronic hepatitis D and non A, non B hepatitis. Hoofnagle JH, Di Bisceglie AM. In, Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. Alan R. Liss, New York 1988;823 830.
29. Effect of recombinant human gamma interferon therapy on immune function in patients with chronic type B hepatitis. Lisker Melman M, Peters M, Ambrus J, Witzel N, Di Bisceglie AM, Kassianides C, Park Y, Murray L, Paxton H, Hoofnagle JH, in: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. Alan R. Liss, New York 1988;868 871.
30. Alpha interferon treatment of patients with decompensated chronic type B hepatitis. Kassianides, Di Bisceglie AM, Hoofnagle JH, Mullen KD, Peters M, Rustgi VK, Jones DB, Lisker-Melman M, Park Y, Waggoner J, Jones EA, in: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. Alan R. Liss, New York 1988;840 843.
31. A randomized, controlled trial of recombinant human alpha interferon in patients with chronic hepatitis B. Hoofnagle JH, Peters M, Mullen K, Jones DB, Rustgi VK, Di Bisceglie AM, Hallahan C, Park Y, Meschievitz C, Jones EA. Gastroenterology 1988;95:1318 1325.
32. The genesis of chronic pancreatitis in the South African black population. Segal I, Lerios M, MacPhail AP, Di Bisceglie AM, Grieve TP. S Afr Med J 1988;74:385 386.
33. Hepatocellular Carcinoma: Molecular biology of its growth and relationship to hepatitis B virus infection. Di Bisceglie AM. Med Clin N Am 1989;73:985 998.
34. Multiple verruciform xanthoma of the upper aerodigestive tract in a child with a systemic lipid disorder. Travis WD, Davis GE, Tsokos M, Lebovics R, Merrick HFW, Miller SPF, Gregg RE, Di Bisceglie AM, Parker RI, Ishak KG, Filling Katz MR. Am J Surg Path 1989;13:309 316.
35. Elevations in serum alpha fetoprotein levels in patients with chronic hepatitis B. Di Bisceglie AM, Hoofnagle JH. Cancer 1989;64:2117 2120.
36. Pityriasis rotunda: a new cutaneous marker of hepatocellular carcinoma? Di Bisceglie AM, Hodkinson HJ, Berkowitz I, Kew MC. Br J Dermatol 1989;120:545 549.
37. Primary hepatic lymphoma of the liver in a patient with acquired immunodeficiency syndrome and chronic hepatitis B. Lisker Melman M, Pittaluga S, Pluda JM, Kleiner DE, Thompson P, Martin P, Yarchoan R, Di Bisceglie AM. Am J Gastroenterol 1989; 84:1445 1448.
38. Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha interferon. Lisker Melman M, Webb D, Di Bisceglie AM, Kassianides C, Martin P, Rustgi V, Waggoner JG, Park Y, Hoofnagle JH. Ann Intern Med 1989;111:479 483.
39. Rapidly progressive non A, non B hepatitis in patients with human immunodeficiency virus infection. Martin P, Di Bisceglie AM, Kassianides C, Lisker Melman M, Hoofnagle JH. Gastroenterology 1989;97:1559 1561.
40. Intrahepatic markers of hepatitis delta virus infection: a study by in situ hybridization. Negro F, Bonino F, Di Bisceglie AM, Hoofnagle JH, Gerin JL. Hepatology 1989; 10:916 920.
41. Interleukin 2 induces profound reversible cholestasis: A detailed analysis in treated cancer patients. Fisher B, Keenan AM, Garra BS, Steinberg SM, White DE, Di Bisceglie AM, Hoofnagle JH, Yolles P, Rosenberg SA, Lotze MT. J Clin Oncol 1989;17:1852 1862.
42. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double blind, placebo controlled trial. Di Bisceglie AM, Martin P, Kassianides C, Lisker Melman M, Murray L, Waggoner JG, Goodman Z, Banks SM, Hoofnagle JH. N Eng J Med 1989;321:1506 1510.
43. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Di Bisceglie AM, Rustgi VK, Kassianides C, Lisker Melman M, Park Y, Waggoner JG, Hoofnagle JH. Hepatology 1990;11:266 270.
44. Cholesteryl ester storage disease: Hepatopathology and effects of therapy with lovastatin. Di Bisceglie AM, Ishak KG, Rabin L, Hoeg J. Hepatology 1990;11:764 772.
45. Significance of hepatitis B core antigen in the liver in patients with chronic hepatitis B and its relation to hepatitis B virus DNA. Yoo JY, Kim HY, Park CK, Khang SK, Jeong JW, Chung WK, Di Bisceglie AM, Hoofnagle JH. J Gastro Hepatol 1990;5:239 243.
46. A randomized, double blind placebo controlled trial of recombinant human alpha interferon therapy for chronic non A, non B (type C) hepatitis. Di Bisceglie AM, Martin P, Kassianides C, Lisker Melman M, Goodman Z, Banks SM, Hoofnagle JH. J Hepatol 1990;11:S36 S42.
47. Therapy of chronic delta hepatitis with interferon alfa-2b. Di Bisceglie AM, Martin P, Lisker Melman M, Kassianides C, Korenman J, Bergasa N, Baker B, Hoofnagle JH. J Hepatol 1990;11:S151 S154.
48. Oligoclonal immunoglobulin bands in serum in association with chronic viral hepatitis. Tsianos EV, Di Bisceglie AM, Papadopoulos NM, Costello R, Hoofnagle JH. Am J Gastroenterol 1990;85:1005 1008.
49. Risk of Non A, Non B (type C) hepatitis through sexual or household contact with carriers. Everhart JE, Di Bisceglie AM, Murray L, Alter HJ, Melpolder JJ, Kuo G, Hoofnagle JH. Ann Intern Med 1990;112:544 545.
50. Detection of hepatitis B virus DNA in serum by polymerase chain reaction: Application for clinical diagnosis. Kaneko S, Miller RH, Di Bisceglie AM, Feinstone SM, Hoofnagle JH, Purcell RH. Gastroenterology 1990;99:799 804.
51. Hepatitis B virus DNA detection and comparison with hepatitis B surface antigen. Kaneko S, Miller RH, Di Bisceglie AM, Feinstone SM, Hoofnagle JH, Purcell RH. Gastroenterol Japonica 1990;25:S57 S61.
52. Hepatitis B viral replication within the human spleen. Di Bisceglie AM, Hoofnagle JH. J Clin Microbiol 1990;28:2850 2852.
53. Antiviral therapy of viral hepatitis. Hoofnagle JH, Di Bisceglie AM. In, Galasso Whitley, Merigan, eds. Antiviral Agents and Viral Diseases of Man, 3rd Edition. 1990;12;415 459.
54. Treatment of chronic non A, non B (type C) hepatitis. Di Bisceglie AM. In, Hollinger B, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Williams and Wilkins, Baltimore 1991;623 626.
55. Loss of hepatitis B surface antigen (HBsAg) following treatment of chronic hepatitis B with alpha interferon. Korenman JC, Baker BL, Waggoner JG, Di Bisceglie AM, Hoofnagle JH. In, Hollinger B, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Williams and Wilkins, Baltimore 1991;639 640.
56. Detection of hepatitis delta virus RNA by in situ hybridization: Virological implications. Negro F, Pacchioni D, Di Bisceglie AM, Gerin JL, Bussolati G, Bonino F. In, Schiraldi O, Pastore G, Dentico P, eds. Progress and prospects in viral hepatitis. Gerni Editori, San Severo 1991;367 370.
57. Detection of hepatitis C viral RNA by the polymerase chain reaction. Cristiano K, Baker B, Di Bisceglie AM, Feinstone SM. In, Hollinger B, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Williams and Wilkins, Baltimore 1991;374 375.
58. Blood borne non A, non B hepatitis: Detection and identification of hepatitis C virus and disease associated antigen (HCV Ag) in hepatocytes. Krawczynski K, Kuo G, Di Bisceglie AM, Bradley D, Houghton M, Alter M, Ebert J. In, Hollinger B, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Williams and Wilkins, Baltimore 1991;434 435.
59. Determination of hepatitis B virus DNA in serum using the polymerase chain reaction: Clinical significance and correlation with serological and biochemical markers. Baker BL, Di Bisceglie AM, Kaneko S, Miller R, Feinstone SM, Waggoner JG, Hoofnagle JH. Hepatology 1991;13:632 636.
60. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Di Bisceglie AM, Order SE, Klein J, Waggoner J, Sjogren M, Kuo G, Houghton M, Choo Q-L, Hoofnagle J. Am J Gastroenterol 1991;86:335 338.
61. Long term remission in chronic hepatitis B after alpha-interferon therapy. Korenman JC, Baker B, Waggoner JG, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Ann Intern Med 1991;114:629 634.
62. Recurrence of hepatitis C virus infection following orthotopic liver transplantation. Martin P, Munoz SJ, Di Bisceglie AM, Rubin R, Waggoner JG, Armenti VT, Moritz MJ, Jarrell BE, Maddrey WC. Hepatology 1991:719 721.
63. Hepatitis C viral RNA in serum of patients with chronic non A, non B hepatitis: Detection by the polymerase chain reaction using multiple primer sets. Cristiano K, Di Bisceglie AM, Hoofnagle JH, Feinstone SM. Hepatology 1991;14: 51 55.
64. Detection of hepatitis C viral RNA in serum of a patient with acute non A, non B hepatitis. Waxman I, Baker B, Feinstone SM, Di Bisceglie AM. Am J Gastroenterol 1991;86:1240 1242.
65. Nodular regenerative hyperplasia of the liver associated with the hypereosinophilic syndrome. Baker B, Di Bisceglie AM, Horwitz ES, Levitt R, Axiotis C. J Clin Gastroenterol 1991;13:452 456.
66. Chronic fatigue syndrome: Lack of association with hepatitis C virus infection. Dale JK, Di Bisceglie AM, Hoofnagle JH, Straus SE. J Med Virol 1991;13:452 456.
67. Diagnostic problems in clinical hepatology. A 20-year old man with persistent aminotransferase elevations. Di Bisceglie AM, Goodman ZD. Semin Liv Dis 1991;11:175 181.
68. The significance of antibody to hepatitis C virus in chronic hepatitis B. Fong T L, Di Bisceglie AM, Waggoner JG, Hoofnagle JH. Hepatology 1991;14:64 67.
69. Decrease in serum hepatitis C viral RNA during alpha interferon therapy for chronic hepatitis C. Shindo M, Di Bisceglie AM, Cheung L, Shih J W K, Cristiano K, Feinstone SM, Hoofnagle JH. Ann Intern Med 1991;115:700 706.
70. Radiologic findings in hepatocellular carcinoma: The National Institutes of Health Experience. Feuerstein IM, Chow CK, Miller DL, Carrasquillo JA, Lotze MT, Di Bisceglie AM. Hepatocellular carcinoma in North America. Portfolio Publishing, Houston 1991;255-272.
71. Replacement therapy for inherited enzyme deficiency: Macrophage targeted glucocerebrosidase for Gaucher Disease. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM and 17 others. N Engl J Med 1991:324:1464 70.
72. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. Fong TL, Shindo M Feinstone SM, Hoofnagle JH, Di Bisceglie AM. J Clin Invest 1991;88:1058 1060.
73. Long term clinical and histopathological follow up of chronic posttransfusion hepatitis. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Hepatology 1991;14:969 974.
74. Development of cirrhosis after chronic type B hepatitis: A clinicopathologic and follow up study of 46 HBeAg positive asymptomatic patients. Moreno Otero R, Garcia Monzon C, Garcia Sanchez A, Buey LG, Pajares JM, Di Bisceglie AM. Am J Gastroenterol 1991;86:560 564.
75. The significance of antibody hepatitis C virus in patients with chronic hepatitis B. Fong TLF, Di Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JH. In, Hollinger B, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Williams and Wilkins, Baltimore 1991; 447 448.
76. Autoimmune thyroid disease associated with recombinant human alpha interferon therapy in patients with chronic viral hepatitis. Lisker Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray L, Hoofnagle JH. Gastroenterology 1992:102:2155 2160.
77. Measurements of iron status in patients with chronic hepatitis. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Gastroenterology 1992;102:2108 2113.
78. Recurrence of hepatitis B and delta hepatitis following orthotopic liver transplantation. Lucey MR, Graham D, Martin P, Di Bisceglie AM, Rosenthal S, Waggoner JG, Merion RM, Campbell DA, Nostrant TT, Appelman H. GUT 1992;33:1390-1396.
79. Acute exacerbation of liver disease during interferon alpha therapy for chronic hepatitis C. Shindo M, Di Bisceglie AM, Hoofnagle JH. Gastroenterology 1992;102:1406 1408.
80. Absence of hepatitis C viral RNA in saliva and semen of patients with chronic hepatitis C. Fried MW, Shindo M, Fong TL, Fox PC, Hoofnagle JH, Di Bisceglie AM. Gastroenterology 1992;102:1306 1308.
81. Transforming growth factor alpha in human hepatocellular carcinoma and co expression with hepatitis B surface antigen in adjacent liver. Hsia C C, Axiotis CA, Di Bisceglie AM, Tabor E. Cancer 1992;70:1049 1056.
82. A pilot study of ribavirin therapy for chronic hepatitis C. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH. Hepatology 1992;16:649 654.
83. A pilot study of 2'3' dideoxyinosine for the treatment of chronic hepatitis B. Fried MW, Korenman JC, Di Bisceglie AM, Park Y, Waggoner JG, Mitsuya H, Hartman NR, Yarchoan R, Broder S, Hoofnagle JH. Hepatology 1992;16:861 864.
84. Hepatitis C virus antigen in hepatocytes: Immunomorphologic detection and identification. Krawczynski K, Beach MJ, Bradley DW, Kuo G, Di Bisceglie AM, Houghton M, Reyes GR, Kim JP, Choo Q L, Alter MJ. Gastroenterology 1992;103: 622 629.
85. Increased expression of transforming growth factor alpha after transfection of a human hepatoblastoma cell line with the hepatitis B virus. Tabor E, Farshid M, Di Bisceglie AM, Hsia CC. J Med Virol 1992;37:271 273.
86. Massive intrahepatic hemorrhage following routine liver biopsy in a patient with rheumatoid arthritis treated with methotrexate. Cash JM, Swain M, Di Bisceglie AM, Wilder RL, Crofford LJ. J Rheumatol 1992;19:1466 1468.
87. Mutations of p53 gene in hepatocellular carcinoma: Roles of hepatitis B virus and Aflatoxin contamination in the diet. Hsia CC, Kleiner DE, Axiotis CA, Di Bisceglie AM, Nomura AMY, Stemmerman GN, Tabor E. JNCI 1992;84:1638 1641.
88. Hepatitis C virus during acute infection in the chimpanzee. Shindo M, Di Bisceglie AM, Biswas R, Mihalik K, Feinstone SM. J Inf Dis 1992;166:424 427.
89. Long term follow up of patients with chronic hepatitis C treated with alpha interferon. Shindo M, Di Bisceglie AM, Hoofnagle JH. Hepatology 1992;15:1013 1016.
90. Hepatitis C viral RNA in serum of patients with chronic non A, non B hepatitis: detection by the polymerase chain reaction using multiple primer sets. Cristiano K, Di Bisceglie AM, Hoofnagle JH, Feinstone SM. Arch Virol 1992;[suppl]4:172 178.
91. Antiviral therapy of hepatitis C: Present and Future. Hoofnagle JH, Di Bisceglie AM, Shindo M. J Hepatol 1993;17:S130 S136.
92. The effect of cholesterol lowering agents on hepatic and plasma cholesterol in Niemann Pick disease, type C. Patterson MC, Di Bisceglie AM, Higgins JJ, Abel RB, Schiffmann R, Parker CC, Argoff CE, Grewal RP, Yu K, Pentchev PG, Brady RO, Barton NW. Neurology 1993;43:61 64.
93. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Hoofnagle JH, Di Bisceglie AM, Waggonner, JG, Park Y. Gastroenterology 1993;104:1116 1121.
94. Gaucher Disease: Abdominal MR Imaging findings in 46 patients. Hill SC, Damaska BM, Ling A, Patterson K, Di Bisceglie AM, Brady RO, Barton NW. Radiology 1992; 184:561 566.
95. Prolonged alpha interferon therapy for chronic delta hepatitis: Effect on liver histopathology. Kleiner D, Di Bisceglie AM, Axiotis CA, Hoofnagle JH. In, Bonino F, Taylor J, Hadziyannis S, eds. Hepatitis Delta Virus. Wiley Liss, New York 1992;365 371.
96. Clinical and serological differentiation of autoimmune and hepatitis C virus related chronic hepatitis. Fried MW, Draguesku JO, Shindo M, Simpson LH, Banks SM, Hoofnagle JH, Di Bisceglie AM. Dig Dis Sci 1993;38:631 636.
97. Persistence of Hepatitis B virus DNA in the liver after loss of HBgAg in chronic hepatitis B. Fong T L, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Hepatology 1993;18:1313 1318.
98. B cell epitopes on the hepatitis C virus nucleocapsid protein determined by human monospecific antibodies. Akatsuka T, Donets M, Scaglione L, Ching W M, Shih JW K, Di Bisceglie AM, Feinstone SM. Hepatology 1993;18:503 510.
99. A 39-year-old man with chronic hepatitis, elevated serum ferritin values, and a family history of hemochromatosis. Bacon BR, Fried MW, Di Bisceglie AM. Seminars in Liver Disease 1993;13:101-105.
100. A randomized, controlled trial of recombinant alpha interferon therapy for chronic hepatitis B. Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J, Bergasa NV, Waggoner JG, Park Y, Hoofnagle JH. Am J Gastroenterol 1993;88:1887 1892.
101. Changes in hepatitis C virus antigen in liver with antiviral therapy. Di Bisceglie AM, Hoofnagle JH, Krawczynski K. Gastroenterology 1993;105:858 862.
102. Detection and quantitation of hepatitis C virus RNA in serum using the polymerase chain reaction and a colorimetric enzymatic detection system. Shindo M, Di Bisceglie AM, Silver J, Limjoco T, Hoofnagle JH, Feinstone SM. J Virol Methods 1994;48:65-72.
103. Therapy of chronic hepatitis B with a 6 month course of ribavirin. Fried MW, Fong T L, Swain MG, Park Y, Beames M, Banks SM, Hoofnagle JH, Di Bisceglie AM. J Hepatol 1994;21:145-150.
104. High levels of viral replication during acute hepatitis B infection predict progression to chronicity. Fong T L, Di Bisceglie AM, Biswas R, Waggoner JG, Wilson L, Clagett J, Hoofnagle JH. J Med Virol 1994;43:155-158.
105. The physical state of the negative strand of hepatitis C virus RNA in serum of patients with chronic hepatitis C. Shindo M, Di Bisceglie AM, Akatsuka T, Fong T-L, Donets M, Hoofnagle JH, Feinstone SM. In, Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Springer-Verlag, New York, 1994;147-149.
106. Hepatitis C viral RNA and hepatic cytokine expression in chronic hepatitis C: The effect of alpha interferon therapy. Shindo M, Hoofnagle JH, Di Bisceglie AM. In, Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Springer-Verlag, New York, 1994;627-630.
107. Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma. Mangia A, Vallari D, Di Bisceglie AM. J Med Virol 1994;43:125-128.
108. The development of a mutation in the pre core region of the hepatitis B virus in a chronically infected individual. Lee JH, Zeldis JB, Baker B, Di Bisceglie AM. Gastroenterology 1994;106:243 247.
109. Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. Di Bisceglie AM, Simpson LH, Lotze MT, Hoofnagle JH. J Clin Gastroenterol 1994;19:222-226.
110. Diagnosis of chronic hepatitis C: Comparison of immunoassays and the polymerase chain reaction. Silva E, Hosein B, Boyle R, Fang C, Shindo M, Waggoner J, Hoofnagle J, Di Bisceglie AM. Am J Gastroenterol 1994;89:493-496.
111. RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus. Hsia CC, Di Bisceglie AM, Kleiner DE, Farshid M, Tabor E. J Med Virol 1994;44:67-73.
112. Hepatitis delta virus RNA in serum of patients with chronic delta hepatitis. Simpson LH, Battegay M, Hoofnagle JH, Waggoner JG, Di Bisceglie AM. Dig Dis Sci 1994;39:2650-2655.
113. The physical state of the negative strand of HCV RNA in serum. Shindo M, Di Bisceglie AM, Akatsuka T, Fong TL, Donets M, Hoofnagle JH, Feinstone SM. In, Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Springer-Verlag, New York 1994;147-149.
114. Hepatitis C viral RNA and hepatic cytokine expression in chronic hepatitis C: The effect of alpha interferon therapy. Shindo M, Hoofnagle JH, Di Bisceglie AM. In, Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Springer-Verlag, New York 1994;627-630.
115. The physical state of the negative strand of hepatitis C virus RNA in serum. Shindo M, Di Bisceglie AM, Akatsuka T, Fong T L, Donets M, Hoofnagle JH, Feinstone SM. Proc Natl Acad Sci USA 1994;91:8719-8723.
116. Increasing HCV RNA levels in hemophiliacs: Relationships to human immunodeficiency infection and liver disease. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Blood 1994;84:1020-1023.
117. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. J Hepatol 1994;21:1109-1112.
118. Changes in levels of HCV-RNA and hepatitis C viral antigen associated with interferon-alpha therapy of chronic hepatitis C. Di Bisceglie AM, Shindo M, Krawczynski K, Hoofnagle JH. In, Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Springer-Verlag, New York 1994;610-613.
119. Genotypic analysis of hepatitis C virus in American patients. Mahaney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, Hoofnagle JH, Sallie R. Hepatology 1994;20:1405-1411.
120. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. Battegay M, Simpson LH, Hoofnagle JH, Sallie R, Di Bisceglie AM. J Med Virol 1994;44:389-392.
121. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C. Olynyk JK, Reddy RK, Di Bisceglie AM, Jeffers LJ, Parker TL, Radick JL, Schiff ER, Bacon BR. Gastroenterology 1995;108:1104-1109.
122. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus encoded peptides binding to HLA-A2.1 molecules. Battegay M, Fikes J, Di Bisceglie AM, Wentwroth PA, Sette A, Celis E, Ching WM, Grakoui A, Rice CM, Kurokohchi K, Berzofsy JA, Hoofnagle JH, Feinstone SM, Akatsuka T. J Virol 1995;69:2462-2470.
123. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with alpha interferon. Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, Di Bisceglie AM. Gastroenterology 1995;109:540-546.
124. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virological and histologic features. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, Di Bisceglie AM, Hoofnagle J. Ann Intern Med 1995;123:330-337.
125. Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. Eyster ME, Sanders JC, Battegay M, Di Bisceglie AM. Dig Dis Sci 1995;40:1583-1588.
126. Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B. Morimitsu Y, Kleiner DE, Conjeevaram HS, Hsia CC, Di Bisceglie AM, Tabor E. Hepatology 1995;22:1021-1026.
127. Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases. Mican J, Di Bisceglie AM, Fong TL, Travis WD, Kleiner DE, Baker B, Metcalfe DD. Hepatology 1995;22:1163-1170.
128. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. Alter HJ, Sanchez-Pescador R, Ureda MS, Wilber JC, Lagier RJ, Di Bisceglie AM, Shih JW, Neuwald PD. J Viral Hepatitis 1995;2:121-132.
129. Hepatic failure and lactic acidosis due to fiauridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, et al. N Engl J Med 1995;333:1099-1105.
130. Idiopathic CD4+ T-lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men. O'Brien TR, Diamondstone L, Fried MW, Aledort LM, Eichinger S, Eyster ME, Hilgartner MW, White G, Di Bisceglie AM, Goedert JJ. Am J Hematol 1995;49:201-206.
131. Fulminant hepatitis in patients undergoing liver transplantation: Evidence for a non-A, non-B, non-C, non-D, and non-E syndrome. Ferraz ML, Silva AE, Macdonald GA, Tsarev SA, Di Bisceglie AM, Lucey MR. Liver Transpl Surg 1996;2:60-66.
132. Ribavirin as therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Wright D, Hoofnagle JH. Ann Intern Med 1996;123:897-903.
133. Seizures during alpha interferon therapy. Shakil AO, Di Bisceglie AM, Hoofnagle JH. J Hepatol 1996;24:48-51.
134. Routes of infection, viremia and liver disease in blood donors found to have hepatitis C virus infection. Conry-Cantilena C, Van Raden M, Gibble J, Melpolder J, Shakil O, Viladomiu L, Chung L, Di Bisceglie AM, Hoofnagle J, Shih J, Kaslow R, Ness P, Alter HJ. N Engl J Med 1996;334:1691-1696.
135. Prolonged therapy of chronic hepatitis C with ribavirin. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. J Vir Hep 1996;3:247-252.
136. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy of chronic hepatitis B. Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM. Am J Gastroenterol 1996;91:1-6.
137. Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg. Mangia A, Chung Y-H, Hoofnagle JH, Birkenmeyer L, Mushahwar I, Di Bisceglie AM. Dig Dis Sci 1996;41:2447-2452.
138. An aflatoxin-associated, mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Soini Y, Chiq SC, Bennett WP, Groopman JD, Wang J-S, DeBenedetti VMG, Cawley H, Welsh JA, Hansen C, Bergasa N, Jones A, Di Bisceglie AM, Trivers GE, Sandoval CA, Calderon IE, Munoz Espinosa LE, Harris CC. Carcinogenesis 1996;17:1007-1012.
139. Rapid development of hepatic alpha-1-antitrypsin globules after liver transplantation for chronic hepatitis C. Combs C, Brunt EM, Solomon H, Bacon BR, Brantly M, Di Bisceglie AM. Gastroenterology 1997;112:1372-1375.
140. Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. Poulos JE, Weber JD, Bellezzo JM, Di Bisceglie AM, Britton RS, Bacon BR, Baldassare JJ. Am J Physiol 1997;273:G804-G811.
141. Assessment of monoethylglycinexylidide as a measure of liver function for patients with viral hepatitis. Elin RJ, Fried M, Sampson M, Ruddel M, Kleiner DE, Di Bisceglie AM. Clin Chem 1997;43:1952-1957 .
142. Geographic distribution and genetic variability of hepatitis delta virus genotype I. Shakil AO, Hadziyuannis S, Hoofnagle JH, Di Bisceglie AM, Gerin JL, Casey JL. Virology 1997;234; 160-167.
143. Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis. Arns PA, Adedoyin A, Di Bisceglie AM, Waggoner JG, Hoofnagle JH, Wilkinson GR, Branch RA. Clinical Pharmacology and Therapeutics 1997;62:527-537.
144. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, Hoofnagle JH, Di Bisceglie AM. Clin Infect Dis 1998;26:895-897.
145. Porphyria cutanea tarda, hepatitis C and HFE gene mutation in North America. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie AM, Tattrie C, Tortorelli K, LeClair P, Mercurio MG, Lambrecht RN. Hepatology 1998;27:1661-1669.
146. Pruritus as a presenting symptom of chronic hepatitis C. Chia S-C, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, Di Bisceglie AM. Dig Dis Sci 1998;43:2177-2183.
147. Hepatitis C virus infection in the mothers and infants cohort study. Granovsky MO, Minkoff HL, Tess BH, Waters D, Hatzakis A, Devoid D, Landesman SH, Rubenstein A, Di Bisceglie AM, Goedert JJ. Pediatrics 1998;102:355-359.
148. Spontaneous bacterial peritonitis caused by infection with Listeria Monocytogenes: A case report and review of the literature. Jayaraj K, Di Bisceglie AM, Gibson S. Am J Gastroenterol 1998;93:1556-1558.
149. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling M-H, Cort S, Albrecht JK (as a member of the Hepatitis Intervention Therapy Group). N Engl J Med 1998;339:1485-1492.
150. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling M-H, Albrecht J (as a member of the Hepatitis Intervention Therapy Group). N Engl J Med 1998;339:1493-1499.
151. Is hepatitis G/GB virus-C virus hepatotropic? Detection of hepatitis G/GB virus-C viral RNA in liver and serum. Fan X, Xu Y, Solomon H, Ramrakhiani S, Neuschwander-Tetri BA, Di Bisceglie, AM. J Med Virol 1998;58:160-164.
152. Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. Fan X, Solomon H, Poulos J, Neuschwander-Tetri BA, Di Bisceglie AM. Am J Gastroenterol 1999;94:1347-1354.
153. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Bassett SE, Di Bisceglie AM, Bacon BR, Sharp RM, Govindarajan S, Hubbard GB, Brasky KM, Lanford RE. Hepatology 1999;29:1884-1892.
154. Seroprevalence of viral hepatitis in an elderly nursing home population. Chien NT, Dundoo G, Horani MH, Osmack P, Morley JE, Di Bisceglie AM, et al. J Am Geriatr Soc 1999;47:1110-1113.
155. Hepatocellular carcinoma not related to hepatitis B virus infection among Alaska natives. Chung Y-H, Di Bisceglie AM, McMahon BJ, Lanier AP, Harpster A, Alter MJ, Parkinson AJ, Zanis C. Internatl J Circumpolar Hlth 1999;58:208-213.
156. Liver transplantation in Patients with chronic hepatitis C and alcoholism. Dhar S, Omran L, Bacon BR, Solomon H, Di Bisceglie AM. Dig Dis Sci 1999;44:2003-2007.
157. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Am J Gastroenterology 1999;94:2467-2474.
158. Resolution of Chronic Delta Hepatitis After 12 Years of Alpha Interferon Therapy. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Gastroenterology 1999;117:1229-1233.
159. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisceglie AM. J Hepatol 2000;32:792-797.
160. Delayed recurrence of hepatocellular carcinoma after liver transplantation: detection of origin by chromosomal analysis. Al-Joundi T, Gibson S, Brunt EM, Shakil O, Lee RS, Di Bisceglie AM. Liver Transplantation 2000;6:374-375.
161. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multi-center, prospective, randomized, controlled trial. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt CM, Tamburro C, Tavill AS, Ferguson DR, Krawitt E, Banner B, Bacon BR. Hepatology 2000;32:135-138.
162. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Brunt EM, Olynyk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR. Am J Gastroenterol 2000;95:1788-1793.
163. A comparison between the phenol-chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of hepatitis C and GB virus-C/hepatitis G viral RNA from serum. Fanson BG, Osmack P, Di Bisceglie AM. J Virol Methods 2000;89:23-27.
164. Hepatic a-smooth muscle actin expression in hepatitis C patients before and after interferon therapy. Khan MA, Poulos JE, Brunt EM, Li L, Solomon H, Britton RS, Bacon BR, Di Bisceglie AM. Hepato-Gastroenterology 2001;48:212-215.
165. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM. Am J Gastroenterol 2001;96:2468-2472.
166. Expression of C-MYC binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma. Fan X, Solomon H, Schwarz K, Kew MC, Ray RB, Di Bisceglie AM. Dig Dis Sci 2001;46:563-566.
167. Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Schwarz KB, Kew M, Klein A, Abrams RA, Sitzmann J, Jones L, Sharma S, Britton RS, Di Bisceglie AM, Groopman J. Dig Dis Sci 2001;46:2173-2178.
168. Differential amplification of hypervariable region 1 (HVR1) of hepatitis C virus by partially mismatched primers. Fan X, Lyra AC, Tan D, Xu Y, Di Bisceglie AM. Biochem Biophys Res Comm 2001;284:694-697.
169. Genetic characterization of hypervariable region 1 in patients chronically infected with genotype 2b hepatitis C virus. Fan X and Di Bisceglie AM. J Med Virol 2001;64:325-333.
170. Cryoglobulinemia associated with Purtscher's-like retinopathy. Myers JP, Di Bisceglie AM, Mann ES. Am J Ophthalmol 2001;131:802-4.
171. A 35 year-old woman with progesterone implant contraception and multiple liver masses. Suarez AA, Brunt EM, Di Bisceglie AM. Semin Liver Dis 2001;21:453-459.
172. Combination of interferon and ribavirin in chronic hepatitis C: Retreatment of nonresponders to interferon. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Hepatology 33:704-707, 2001.
173. Complement mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C E2 chimeric glycoprotein. Meyer K, Basu A, Przysiecki CT, Lagging LM, Di Bisceglie AM, Conley AJ, Ray R. J Virol 2002;76:2150-2158.
174. A 32 year-old man with hepatitis C who developed progressive liver failure after a bone marrow transplant. Lyra AC, Brunt EM, Pincus S, Di Bisceglie AM. Seminars in Liver Disease 2002;22:103-107.
175. Direct evidence for GB virus C/hepatitis G virus (GBV-C, HGV) superinfection: Elimination of resident viral strain by donor strain in a patient undergoing liver transplantation. Fan X, Xu Y, Detre K, Di Bisceglie AM. J Med Virol 2002;68:76-81.
176. Evidence for probable sexual transmission of the hepatitis G virus. Frey SE, Homan SM, Sokol-Anderson M, Torralba Cayco M, Cortorreal P, Musial C, Mushahwar IK, Di Bisceglie AM. Clin Infect Dis 2002;34:1033-8.
177. Genetic complexity and serum reactivity of HVR1 quasispecies of hepatitis C virus patients with cirrhosis. Fan X, Di Bisceglie AM. Am J Gastroenterol 2002;97:1489-1495.
178. Evolution of hepatitis C viral quasispecies after liver transplantation. Lyra AC, Fan X, Ramrakhiani S, Brunt EM, Di Bisceglie AM. Gastroenterology 2002;123:1485-1493.
179. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Brunt EM, Ramrahkiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM. Mod Pathol 2003:16:49-56.
180. Hepatitis C-related hepatocellular carcinoma in the United States: Influence of ethnic status. Di Bisceglie AM, Lyra AC, Schwarz M, Reddy RK, Martin P, Gores G, Lok ASF, Hussein K, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS; Liver Cancer Network. Am J Gastroenterol 2003;98:2060-3.
181. Liver Transplantation With Hepatitis C Virus-infected Graft: Interaction Between Donor And Recipient Viral Strains. Fan X, Lang DM, Xu Y, Lyra AC, Yusim K, Everhart JE, Korber BTM, Perelson AS, Di Bisceglie AM. Hepatology 2003;38:25-33.
182. Accumulation of B lymphocytes with a naïve, resting phenotype in a subset of hepatitis C patients. Li, J, Mebrador E, Di Bisceglie AM, Jacobson IM, Talal AH, Butera D, Rice CM, Chambers TJ, Dustin LB. J Immunol 2003;170:3429-3439.
183. Molecular and serological aspects of HBsAg-negative hepatitis B virus infections in North America. Hsia CC, Scudamore CH, Di Bisceglie AM, Tabor E. J Med Virol 2003;70:20-26.
184. Diversification of hypervariable region 1 of hepatitis C virus after liver transplantation. Fan X, Di Bisceglie AM. J Med Virol 2003;70:212-218.
185. Infection with hepatitis C virus genotype 4 in the United States. Lyra AC. Ramrakhiani S. Bacon BR. Di Bisceglie AM. J Clin Gastroenterol 2004;38:68-71.
186. Biliary-Venous Fistula Complicating Transjugular Intrahepatic Portosystemic Shunt Presenting With Recurrent Bacteremia, Jaundice, Anemia and Fever. Jawaid Q, Saeed ZA, Di Bisceglie AM, Brunt EM, Ramrakhiani S, Varma CR, Solomon S. Am J Transplantation 2003;3:1-4.
187. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis: A case report. Brunt EM, Di Bisceglie AM. Human Pathology 2004;35:509-512.
188. HCV E2 glycoprotein: Mutagenesis of the N-linked glycosylation sites and effects on protein expression and secretion. Slater-Handshy T, Droll D A, Fan X, Di Bisceglie AM, and Chambers T. Virology 2004;319:36-48.
189. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, Cooper JN, Di Bisceglie AM, Seneca R, Younossi ZM. Dig Dis Sci 2004;49:850-3.
190. Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostaining. Richart J, Brunt EM, Di Bisceglie AM. Dig Dis Sci 2002;47:2454-8.
191. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE, and the HALT-C Trial Group. Gastroenterology 2004;126:1015-1023.
192. A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: Does nursing play a role? Strinko JM, Di Bisceglie AM, Hoffmann JA. Issues Mental Health Nurs 2004;25:715-722.
193. Evolution of the HALT-C trial: Pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE, and the HALT-C Trial Group. Lee WM, Bonkovsky H, Di Bisceglie AM et al. Contr Clin Trials 2004;25:472-492.
194. Associations among clinical, histologic, immunologic and viral quasispecies measures in advanced chronic hepatitis C: Baseline analysis of the HALT-C trial. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM et al. Hepatology 2005;41:617-625.
195. CD81 binding regions of hepatitis C virus remain conserved after liver transplantation. Lyra AC, Fan X, Di Bisceglie AM. Braz J Infect Dis. 2004;8:126-132.
196. Quasisecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells M, Dustin LB, Di Bisceglie AM. J Virology 2005;79:3071-3083.
197. -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
198. --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
199. ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
MANUSCRIPTS SUBMITTED FOR PUBLICATION
1. -----------------------------------------------------------------------------------------------------------------------------------------
2. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
3. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------.
REVIEWS, EDITORIALS, AND BOOK CHAPTERS:
1. Cirrhosis and chronic pancreatitis in alcoholics. (Editorial). Di Bisceglie AM and Segal I. J Clin Gastroenterol 1984;6:199 200.
2. Biliary obstruction due to chronic pancreatitis. Di Bisceglie AM and Segal I. Tropic Gastroenterol 1984;5:29 34.
3. Hepatitis B virus infection and hepatocellular carcinoma. Etiologic relationship and clinical implications. Di Bisceglie AM and Hoofnagle JH. In, DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and practice of Oncology (updated). J.B. Lippincott Co. 1987;1-10.
4. Management of post transfusion hepatitis. Hoofnagle JH, Di Bisceglie AM, Lisker Melman M, Kassianides C, Martin P. Trans Med Rev 1988;2:215 220.
5. Hepatocellular carcinoma. Di Bisceglie AM, moderator. Proceedings of NIH Combined Clinical Staff Conference. Ann Int Med 1988:108;390 401.
6. Treatment of chronic type B hepatitis. Di Bisceglie AM, Hoofnagle JH. Cancer Detect Prevent 1989;14:291 294.
7. Interferon therapy of complicated hepatitis B infection. Di Bisceglie AM. Semin Liver Dis 1989;9:254 258.
8. Interferon therapy of chronic type C hepatitis. Hoofnagle JH, Di Bisceglie AM. Semin Liver Dis 1989;9:259 263.
9. Diagnosis of hepatitis delta virus infection (Editorial). Di Bisceglie AM, Negro F. Hepatology 1989;10:1014 1016.
10. Antiviral therapy of viral hepatitis. Hoofnagle JH, Di Bisceglie AM. Antiviral Agents and Viral Diseases of Man. 3rd ed. 1990;415-459.
11. Treatment of chronic non A, non B (type C) hepatitis. Hoofnagle JH, Di Bisceglie AM. In, Shikata T, Purcell RH, Uchida T, eds. Viral hepatitis C, D, E. Elsevier, Amsterdam 1991;151 156.
12. Therapy of chronic hepatitis C with alpha interferon (Editorial). The answer? or More Questions? Di Bisceglie AM, Hoofnagle JH. Hepatology 1991;13:601 603.
13. Serologic diagnosis of acute and chronic viral hepatitis. Hoofnagle JH, Di Bisceglie AM. Semin Liv Dis 1991;11:73 83.
14. Chronic viral hepatitis and hepatocellular carcinoma. Di Bisceglie AM. In, Tabor E, Di Bisceglie AM, Purcell RH, eds. Hepatocellular Carcinoma in North America. Portfolio Publishing. Houston 1991;127-138.
15. Delta hepatitis. Di Bisceglie AM. In, Perrillo RP, ed. Hepatitis. Viral and drug induced. National Health Labs. La Jolla. 1991;19 26.
16. Therapy of chronic delta hepatitis: An overview. Hoofnagle JH, Di Bisceglie AM. In, Bonino F, Taylor J, Hadziyannis S, eds. Hepatitis Delta Virus. Wiley Liss, New York 1993;337-343.
17. Natural history of hepatitis D virus. Conjeevaram H, Di Bisceglie AM. In, Zuckerman AJ, Thomas HC, eds. Viral hepatitis (1st Ed). Churchill Livingstone. 1993;341 350.
18. Epidemiology and Diagnosis of hepatitis D virus. Di Bisceglie AM. In, Zuckerman AJ, Thomas HC, eds. Viral hepatitis (1st Ed). Churchill Livingstone 1993;351 362.
19. Metabolic diseases of the liver. Fried MW, Di Bisceglie AM. In, Rustgi VK, Van Thiel DH, eds. The liver in systemic disease. Raven Press, New York 1993;167 189.
20. Alpha interferon therapy for chronic viral hepatitis: From bench to approval. Di Bisceglie AM, Hoofnagle JH. In, Strand V, ed. Biologic Agents in Autoimmune Diseases. Arthritis Foundation, Atlanta 1994;65-69.
21. Interferon therapy of chronic viral hepatitis. Di Bisceglie AM. New Eng J of Med 1994;330:137-138 .
22. Viral hepatitis and hepatocellular carcinoma. Sallie R, Di Bisceglie AM. In, Martin P, Friedman L, eds. Clin Gastroenterol 1994;23:567-579.
23. Interferon therapy for chronic viral hepatitis (Editorial). Di Bisceglie AM. N Engl J Med 1994;350:137 138.
24. Extra-hepatic manifestations of chronic viral hepatitis. Shakil OA, Di Bisceglie AM. 'L' Internista' 1994;2:139-144.
25. Hepatitis C and hepatocellular carcinoma. Di Bisceglie AM. Semin Liver Dis 1995;15:64-69.
26. New treatments for chronic hepatitis B. Di Bisceglie AM. In, Arroyo V, Bosch J, Rodes J, eds. Treatments in Hepatology. Masson, S.A., Barcelona 1995;203-206.
27. Management of chronic viral hepatitis in children. Conjeevaram H, Di Bisceglie AM. J Ped Gastro Nutr 1995;20:365-375.
28. Long-term outcome of alpha interferon therapy for chronic hepatitis B. Di Bisceglie AM. J Hepatol 1995;22(Suppl):65-67.
29. Chronic hepatitis B: Hope for decreasing its impact. Di Bisceglie AM. Postgraduate Medicine 1995;98:99-106.
30. Liver transplantation for hepatitis C: The promise and the challenge. Di Bisceglie AM. Hepatology (Editorial) 1995;22:660-662.
31. New hepatitis viruses: Adding to the alphabet soup (Editorial). Di Bisceglie AM. Viral Hepatitis Reviews 1995;1:3-5.
32. Tumors of the liver. Di Bisceglie AM, Buetow PC. In, Maddrey WC, Feldman M, eds. Gastroenterology and Hepatology: The Comprehensive Visual Reference (The Liver) 1995;1:13.2-13.13.
33. Tumors of the liver. Di Bisceglie AM. In, Bone RC, ed. Current Practice of Medicine 1996;4:15.1-15.8.
34. Chronic viral hepatitis. Di Bisceglie AM, Hoofnagle JH. In, Zakim D, Boyer T, eds. Hepatology 3rd edition, Philadelphia 1996;1299-1329.
35. Liver. Di Bisceglie AM, Tabor E. Cancer Rates and Risks (4th edition). National Institutes of Health, National Cancer Institute 1996;155-157.
36. Interpreting serologic tests for hepatitis C virus infection: balancing cost and clarity. Long GS, Bacon BR, Di Bisceglie AM. Clev Clin J Med 1996;63:264-268.
37. Hepatitis G virus infection -- a work in progress (Editorial). Di Bisceglie AM. Ann Intern Med 1996;125:772-773.
38. Thymus-derived peptides for chronic viral hepatitis: Have they fulfilled their promise? (Editorial) Di Bisceglie AM. Dig Dis 1996;14:331-333.
39. Hepatitis D Virus. Di Bisceglie AM. In, Willson R, eds. Viral Hepatitis, Marcel Dekker, New York; 1996;217-238.
40. The treatment of chronic viral hepatitis. Hoofnagle JH, Di Bisceglie AM. N Engl J Med; 1997;347-356.
41. Hepatitis C. Di Bisceglie AM. The Lancet 1998;351:351-55.
42. Hepatitis C: Clinical aspects and therapy. Di Bisceglie AM, Rakela J. In, Rizetto M, ed. Viral Hepatitis and Liver Diseases; Proceedings of the IXth Triennial Int'l Symposium on Viral Hepatitis and Liver Diseases. 1997;916-918.
43. Consultants and Comments: Preventing sexual transmission of hepatitis C. Di Bisceglie AM. Consultant 1997, p. 1774.
44. Hepatic tumors. Di Bisceglie AM. In, Friedman LS, Keefe E, eds. Handbook of Liver Diseases. Churchill Livingstone, Edinburgh 1998;361-372.
45. Management of chronic viral hepatitis. Di Bisceglie AM, Hoofnagle JH. In, Di Bisceglie AM, Bacon BR, eds. Liver Disease: Diagnosis and Management. Churchill Livingstone, New York, 1999, pp. 98-106.
46. Consensus3: The coming of age of hepatitis C. Di Bisceglie AM (Editorial). Viral Hepatitis Reviews 1997;3:201-202.
47. Hepatitis C and hepatocellular carcinoma. Di Bisceglie AM. Hepatology 1997;26:34S-38S.
48. Hepatitis G virus infection around the world: Prevalence, mode of transmission risk factors and association with hepatitis. Shah D, Mitra AK, Di Bisceglie AM. Viral Hepatitis Reviews 1997;3:179-188.
49. Diagnosis and treatment of hepatocellular carcinoma. Di Bisceglie AM. Gastroenterology 1997;113:1807-1809.
50. The Liver Mass--Clinical. Di Bisceglie AM. In, Bloomer JR, Goodman ZD, Ishak KG. Clinical and Pathological Correlations in Liver Disease: Approaching the Next Millennium 1998;97-102.
51. Natural history of hepatitis D virus. Conjeevaram H, Di Bisceglie AM. In, Zuckerman AJ, Thomas HC, eds. Viral hepatitis (2nd Edition). Churchill Livingstone 1998;379-385.
52. Epidemiology and Diagnosis of hepatitis D virus. Di Bisceglie AM. In, Zuckerman AJ, Thomas HC, eds. Viral hepatitis (2nd Edition). Churchill Livingstone 1998;371-378.
53. Hepatocellular carcinoma. Di Bisceglie AM, Carithers Jr. RL, Gores GJ. Hepatology 1998;28:1161-1165.
54. Hepatocellular carcinoma. Tabor E, Di Bisceglie AM. Clinics in Liver Disease 1999;3:327-348.
55. Malignant neoplasms of the liver. Di Bisceglie AM. In, Schiff ER, Maddrey WC, Sorrell M, eds. Schiff's Diseases of the Liver (8th edition) Lippincott-Raven, 1999;1281-1303.
56. Viral Hepatitis. Di Bisceglie AM. In, Dolin R, Masur H, Saag M, eds. AIDS Therapy. Churchill Livingstone 1999;516-529.
57. Management of Tumors of the Liver. Stribling R, Martin P, Di Bisceglie AM. In, Wolfe MM, ed. Therapy of Digestive Disorders, 1999; Chapter 102, pp. 901-904.
58. Tumors of the liver. Di Bisceglie AM. Current Practice Medicine 1999;2:109-116.
59. Iron and viral hepatitis. Di Bisceglie AM. In, Arroyo V, Bosch J, Bruguera M, Rodes J, Sanchez Tapias JM. Treatment of Liver Diseases. Masson, Barcelona. 1999, pp. 307-310.
60. Viral Hepatitis. Di Bisceglie AM. In, Digestive Disease Self-Evaluation Program (DDSEP) for the American Gastroenterological Association, 1999.
61. Hepatitis B. Befeler AS and Di Bisceglie AM. In, Infectious Disease Clinics of North America 1999;14:617-632.
62. Management of Tumors of the Liver. Di Bisceglie AM and Richart JM. In, Wolfe MM, ed. Therapy of Digestive Disorders: A Companion to Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 1999, pp. 421-428.
63. Hepatitis C - Virology and future antiviral targets. Di Bisceglie AM. Am J Med 1999; 107(6B):45S-48S.
64. Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases. Di Bisceglie AM. Am J Med 1999;107(6B):53S-56S.
65. Di Bisceglie AM: Tumors of the Liver. Current Practice of Medicine [serial online: http://praxis.md]. 2000 Jan; 3(1).
66. Tumors of the liver. Di Bisceglie AM, Buetow PC. In, Maddrey WC, Feldman M, eds. Gastroenterology and Hepatology: The Comprehensive Visual Reference (The Liver, 2nd Edition), 2000, pp. 13.1-13.14.
67. The10th triennial meeting on viral hepatitis and liver diseases, Atlanta, 9 to 13 April 2000: A personal perspective. Di Bisceglie AM. Viral Hepatitis Reviews 2000;6:1-3.
68. Hepatocellular carcinoma. Di Bisceglie AM. Clin Perspectives in Gastro 2000;3:33-39.
69. Natural history of hepatitis C: Its impact on clinical management. Di Bisceglie AM. Hepatology 2000;31:1014-1018.
70. New developments in hepatocellular carcinoma. Di Bisceglie AM. Online presentation: www.medscape.com/Medscape/CNO/2000/AASLD/Story for the American Association for the Study of Liver Diseases 51st Annual Meeting and Postgraduate Course, 2000.
71. Hepatitis and hepatocellular carcinoma. Di Bisceglie AM. In Hepatitis C. Academic Press, 2000, pp. 265-275.
72. Hepatitis C - evolving therapeutic strategies. Di Bisceglie AM. In, Boyer JL, Blum HE, Maier K-P, Sauerbruch T, Stalder GA, eds. Liver Cirrhosis and Its Development. Falk Symposium 115, 2001, pp. 156-160.
73. Liver Tumors. Di Bisceglie, AM. In, Clinics in Liver Disease, Guest Editor. W.B. Saunders Co., Philadelphia. Vol. 5, February 2001.
74. Preventive strategies for chronic liver disease (editorial). Di Bisceglie AM. American Family Physician 2001;64:1515-1516.
75. Liver diseases. Instructional pamphlet written for SLUCare/Tenet, 2001.
76. An error rationalized is still a mistake. Di Bisceglie AM. Lancet 2002;360:1688 (commentary).
77. SEN and sensibility: Interactions between newly discovered and other hepatitis viruses? Di Bisceglie AM. Lancet 2001;358:1925-1926 (commentary).
78. Compartmentalization of hepatitis C viral quasispecies. Fan X, Castro-Lyra A, Di Bisceglie AM. In Therapies for Viral Hepatitis. Schinazi RF, Rice C, and Sommadossi J-P (eds). Elsevier Science, The Netherlands, January 2002, pp. 123-130.
79. --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
80. Cystic and nodular diseases on the liver. Di Bisceglie AM and Befeler AS. In Schiff's Diseases of the Liver, Ninth Edition. Schiff ER, Sorrell MF, Maddrey WC (eds). Lippincott Williams and Wilkins. Philadelphia. pp. 1149-1168.
81. Treatment of hepatocellular carcinoma. In, Viruses and Liver Cancer. Befeler A and Di Bisceglie AM. Tabor E (ed), Elsevier Science B.V., The Netherlands, 2002, pp. 161-172.
82. Viral Hepatitis. Di Bisceglie AM. In, Digestive Disease Self-Evaluation Program (DDSEP II) for the American Gastroenterological Association, 2002.
83. Hepatocellular carcinoma: Diagnosis and treatment. Befeler AS, Di Bisceglie AM. Gastroenterology 2002;122:1609-1619.
84. What is the optimal therapy for chronic hepatitis B? Lyra AC, Di Bisceglie AM. Minerva Medica 2002;96:431-434.
85. Combination therapy for hepatitis B. Di Bisceglie AM. Gut 2002;50:443-446.
86. Epidemiology and clinical presentation of hepatocellular carcinoma. Di Bisceglie AM. JVIR 2002:13:S169-S171.
87. Optimal therapy of hepatitis C. Di Bisceglie AM and Hoofnagle JH. Hepatology 2002;36:S121-S127.
88. Hepatitis C - Current diagnosis and emerging treatment options. Di Bisceglie AM. Thomson PDR, Montvale, NJ. 2003. pp. 1 - 16.
89. Tumors of the liver. Di Bisceglie AM. In, Maddrey WC and Feldman M, eds. Atlas of the Liver (3rd Edition). Current Medicine, Philadelphia. 2003, pp. 287-301.
90. Hepatitis and hepatocellular carcinoma. Di Bisceglie AM. In, Buti M, Esteban R, eds. Viral Hepatitis. Accion Medica SA, Madrid. 2003. pp. 133-138.
91. Viral Hepatitis. Di Bisceglie AM. In, Digestive Disease Self-Evaluation Program (DDSEP III) for the American Gastroenterological Association. Chapter 13, pp. 271-288, 2004.
92. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Harrison SA and Di Bisceglie AM. Drugs 2003;63:2379-2394.
93. What every hepatologist should know about endocrinology: Obesity, diabetes, and liver disease (editorial). Di Bisceglie AM. Gastroenterology 2004;126:604-606.
94. Screening in liver disease. Adams PC, Arthur MJ, Blanck Heidi, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Hepatology 2004;39:1204-1212.
95. Hepatic tumors. Di Bisceglie AM. In, Friedman LS, Keeffe EB, eds. Handbook of liver disease. Second edition. Churchill Livingstone. Philadelphia. 2004. pp. 339-348.
96. Molecular biology and clinical implication of hepatitis C virus. Lyra AC, Fan X, Di Bisceglie AM. Brazilian J Med Biol Res 2004;37:691-695.
97. New therapeutic strategies in hepatitis C. Di Bisceglie AM, McHutchison J, Rice CM. Hepatology 2002;35:224-231.
98. Foreword: Advances in the treatment of chronic hepatitis C. Di Bisceglie AM. Seminars in Liver Disease 1999;19:1-2.
99. The unmet challenge of hepatitis C. Di Bisceglie AM and Bacon BR. Scientific American 1999 (Oct.):58-63.
100. Issues in screening and surveillance for hepatocellular carcinoma. Di Bisceglie AM. Gastroenterology 2004;127:S104-S107..
101. Screening for hepatocellular carcinoma: Being old is not all bad. Di Bisceglie AM. Am J Gastroenterol 2004;99:1470-6.
102. Screening for hepatocellular carcinoma. Bialecki E, Di Bisceglie AM. In, McHutchison J, ed. Management issues in hepatitis C infection. Science Press. London. 2004. pp. 118-121.
103. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004;141:715-17.
104. Diagnosis of hepatocellular carcinoma. Bialecki ES, Di Bisceglie AM. (2005) HPB Journal (in press)
105. --------------------------------------------------------------------------------------------------------------------------------
106. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: Presentation, screening, prevention, and treatment of hepatocellular carcinoma - Part I. Hayashi PH, Di Bisceglie AM. Med Clin N Am 2005;89:345-370.
107. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: Presentation, screening, prevention, and treatment of hepatocellular carcinoma - Part II. Hayashi PH, Di Bisceglie AM. Med Clin N Am 2005;89:371-390.
108. -------------------------------------------------------------------------------------------------------------------------------------
LETTERS OF SCIENTIFIC INTEREST, OTHER MISCELLANEOUS PUBLICATIONS:
1. Terminology of sclerosing cholangitis. Di Bisceglie AM, Segal I. J Clin Gastroenterol 1982;4:480.
2. Plasmodium falciparum malaria in the Southern Transvaal. Di Bisceglie AM. S Afr Med J 1985;67:529.
3. (Comment) Transgenic mouse model for the chronic hepatitis B surface antigen carrier state. Di Bisceglie AM and Hoofnagle JH. Hepatology 1986;6:532 533.
4. Recombinant α-interferon: a promissory note in non-A, non-B chronic hepatitis. Hoofnagle JH, Di Bisceglie AM. Gastroenterology 1987;93:658-659.
5. (Tape) Treatment of chronic viral hepatitis. Di Bisceglie AM. Practical Reviews in Gastroenterology 1989;3.
6. Antibody to hepatitis C virus in patients with chronic non A, non B hepatitis and other chronic liver diseases. Di Bisceglie AM. Liver Update 1990;4:3 4.
7. Factors predicting the outcome of alpha interferon therapy for chronic non A, non B (type C) hepatitis. Di Bisceglie AM. Liver Update 1990;4:5 6.
8. Development of cirrhosis following chronic non A, non B hepatitis. Di Bisceglie AM. Liver Update 1988;2:3 4.
9. (Book Review) Neoplasms of the liver. Di Bisceglie AM. Hepatology 1988;8:1178 79.
10. (Comment) Treatment of hepatocellular carcinoma. Di Bisceglie AM. Hepatology 1991;13:802 803.
11. Hepatocellular carcinoma: Recent developments. Di Bisceglie AM. Prac Rev Gastro 1991; 5: No 8.
12. Early diagnosis of hepatocellular carcinoma in Italy. Dioguardi N, Barbara L, Bolondi L, Colombo M, Di Bisceglie AM, Dusheiko G, Gozzetti G, Ohto M, Okuda K, Verme G. J Hepatology 1992;14:401-403.
13. (Book review) The hepatitis delta virus. Di Bisceglie AM. Gastroenterology 1993;105:1586 1588.
14. Correspondence (reply): Aspartate aminotransferase and iron status - lack of support for covariation. Bacon BR and Di Bisceglie AM. Gastroenterology 1993;104:665.
15. (Book review) Histopathology of the liver. Di Bisceglie AM, Hoofnagle JH. Gastroenterology 1994;107:598-599.
16. Combined infection with hepatitis B and hepatitis C. Di Bisceglie AM. Hepatitis forum. Abbott Labs 1994;p.12.
17. (Tape) Hepatitis C recommendations. Di Bisceglie AM. Audio Journal of Haematology. 1994;2 No 1.
18. (Images in Medicine) A patient with cryoglobulinemia and hepatitis C. Shakil AO, Di Bisceglie AM. N Engl J Med 1994;331:1624.
19. (Letter) Absence of hepatitis C viral infection among patients with primary Sjogren's syndrome. Marrone A, Di Bisceglie AM, Fox P. J. Hepatol 1995;22:599.
20. Foreword for Viral Hepatitis Reviews. Di Bisceglie AM. Viral Hepatitis Reviews 1995;1:1.
21. Is there a role for hepatitis B vaccine in cirrhosis? Di Bisceglie AM, Consultant. June, 1995;762.
22. A link between chronic hepatitis B and recurrent cellulitis? Di Bisceglie AM, Consultant June, 1996;1110.
23. (Highlights from the Int'l Congress of Internal Medicine Manila, 1996) Seroprevalence of hepatitis B and C: Asians vs. Caucasians. Di Bisceglie AM. Excepta Medica 1996;1-4.
24. (Letter) Ribavirin for chronic hepatitis C. Di Bisceglie AM, Hoofnagle JH. Ann Intern Med 1996; 125:699.
25. Hepatocellular carcinoma. Di Bisceglie AM. The clinician's companion: expert perspectives on contemporary clinical issues in hepatitis C. 1997;39-40.
26. Emerging therapies for chronic hepatitis C. Audiotape: Beyond Monotherapy: Next Generation Therapies for Chronic Hepatitis C. Di Bisceglie AM. Education Initiative in Gastroenterology Meeting, New Orleans, May 17, 1998.
27. What next when a patient with hepatitis C refuses biopsy? (Editorial) Di Bisceglie AM. Consultant 1999;39:614.
28. Is therapy warranted in an older patient with hepatitis C? (Editorial) Di Bisceglie AM. Consultant 1999;39:1639.
29. The Clinician's Companion III: Expert perspectives on contemporary clinical issues in hepatitis C. CD-ROM. Di Bisceglie AM. Education Initiatives in Gastroenterology Meeting, June 18-19, 1999.
30. Rising Incidence of Hepatocellular Carcinoma. Di Bisceglie, AM. Medscape AASLD - Advances in Hepatocellular Carcinoma December 1999. Available at: http://gastroenterology.medscape.com/Medscape/CNO/1999/AASLD/public/index-AASLD.html.
31. "Viral Hepatitis." Di Bisceglie AM. In Digestive Diseases Self-Education Program II for the American Gastroenterological Association, 2000.
32. "How do you manage the patient with hepatitis B and hepatitis C dual infection?" Di Bisceglie AM. Medscape "Ask the Experts-Hepatitis C," December 14, 2000. Available at: http//www.medscape.com/medscape/features/ResourceCenter/HepC/AskExperts/2000/12/ HepC-ae08.html.
33. "Raising hepatitis C awareness." Di Bisceglie AM. HealthTalk Interactive's Hepatitis C Education Network, January 30, 2001. Available at http://www.healthtalk.com.
34. The Clinician's Companion IV: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C. Part 3: Insights into pathogenesis, treatment effects, and management of advanced liver disease. "Management of HCV-related cirrhosis and hepatocellular carcinoma." Projects in Knowledge, 2001, pp. 9-12. Di Bisceglie AM, Kwo PY, Rustgi VK.
35. (Consultations and Comments) Monoclonal gammopathy associated with hepatitis C - or something else? Di Bisceglie AM. Consultant 2001;41:650.
36. Letter to the Editor regarding "Hepatitis C Virus Infection" by Lauer and Walker. Bacon BR and Di Bisceglie AM. N Engl J Med, 2001;345:1425-1426.
37. Di Bisceglie AM, Rakela J. Hepatocellular carcinoma. In, The Clinician's Companion V: Expert perspectives on contemporary issues in hepatitis C. Part 2: Insights into the pathogenesis, treatment effects and management of advanced liver disease. Projects in Knowledge 2001. pp. 11-15.
38. Nonalcoholic liver disease: An emerging view of its significance and management. Di Bisceglie AM. Medscape Gastroenterology/DDW 2002 Conference Coverage. Available at http://www.medscape.com/viewprogram/1846.
39. Hepatitis C Virus (book review). Di Bisceglie AM. Gastroenterology 2000;116:224-225.
40. Natural history of hepatitis C. Di Bisceglie AM. In, Clinical Care Options for Hepatitis. Annual Update 2003. IMedOptions. pp. 3-12.
41. Malignant Liver Tumors: Current and Emerging Therapies (book review). Di Bisceglie AM. New Engl J Med 2004;350:202-203.
42. http://www.medscape.com/viewprogram/3103. Di Bisceglie AM. DDW 2004 CME Program.
43. Hepatocellular carcinoma. Di Bisceglie AM. In, In, Clinical Care Options for Hepatitis. Annual Update 2004. IMedOptions. pp. 149-158.
44. Distribution of hepatitis B virus (HBV) genotypes among patients with acute viral hepatitis. Lyra AC, Pinho JRR, Mello IMVGC, Malta F deM, Gomes MMS, Di Bisceglie AM, Lyra LGC, Carrilho FJ, da Silva LC. J Clin Gastroenterol 2005;39:81-81 (letter).
45. The Clinician's Companion VII: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C. "Relationship between chronic HCV infection and hepatocellular carcinoma." Projects in Knowledge, 2005, pp. 53-57. Di Bisceglie AM.
46. -----------------------------------------------------------------
ABSTRACTS
1. Why does alcohol affect the liver and pancreas differentially? Di Bisceglie AM, Segal I, Rabson AR, Diamond TH. Presented at annual meeting of South African Gastroenterology Society (SAGES) at Sun City, 1982.
2. Obstructive jaundice in South African Blacks. Di Bisceglie AM, Segal I, Oettle GJ, Hodkinson HJ . SAGES meeting, Cape Town, 1983.
3. Detection of markers of hepatitis B virus infection in urine of chronic carriers. Di Bisceglie AM, Dusheiko GM, Kew MC. S Afr Med J, 1984.
4. Liver histopathology in biliary obstruction due to chronic pancreatitis. Di Bisceglie AM, Paterson AC and Segal I. S Afr Med J, 1984.
5. Hepatitis B replication in adult carriers in an endemic area. Dusheiko GM, Bowyer S, Santos AP, Wolf P, Di Bisceglie AM, Song E, Kew MC. Hepatology 1983;3:809.
6. Detection of alphafoetoprotein messenger RNA in human hepatocellular carcinoma tissue. Di Bisceglie AM, Dusheiko GM, Ritchie M, Lee C S, Beasley RP, Shouval D, Kew MC. Hepatology 1984;4:1042.
7. Prolonged recombinant leucocyte interferon (IFLA) treatment of chronic hepatitis. Dusheiko GM, Di Bisceglie AM, Bowyer S, Sacks E, Kew MC. 1984 International Symposium on Viral Hepatitis 1984; San Francisco.
8. Hepatitis B virus infection in urban black children in Soweto. Di Bisceglie AM, Dusheiko GM, Song E, Paterson AC Kew MC. Hepatology 1985;5:1046.
9. Obstructive jaundice in South African black and white populations: a retrospective study. Danilewitz M, Segal I, Di Bisceglie AM, Bank L. S Afr Med J 1985;68;521.
10. Changes in liver hepatitis B virus DNA associated with sero conversion from hepatitis B e antigen to antibody in chronic hepatitis B. Di Bisceglie AM, Hoofnagle JH. Gastroenterology 1986;90:1721.
11. Localization of the p 450 system in liver by in situ hybridization. Rustgi VK, Jones DB, Di Bisceglie AM, Hoofnagle JH, Jones EA. Hepatology 1986;6:1220.
12. Detection of hepatitis B virus X gene protein in human hepatocellular carcinoma tissue by western blot. Di Bisceglie AM, Feinstone SF, Sninsky J, Kew MC, Dusheiko GM, Hoofnagle JH. Hepatology 1986;6:1220.
13. Loss of hepatitis B surface antigen from serum of chronic carriers. Di Bisceglie AM, Waggoner JG, Hoofnagle JH. Hepatology 1986;6:1220.
14. Treatment of chronic non A non B hepatitis with recombinant human alpha interferon. Hoofnagle JH, Mullen KD, Jones DB, Rustgi VK, Di Bisceglie AM, Peters MG, Waggoner JG, Park Y, Jones EA. Hepatology 1986;6:1220.
15. Randomized controlled trial of a four month course of recombinant human alpha interferon in patients with chronic type B hepatitis. Di Bisceglie AM, Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi VK, Avigan MI, Park Y, Waggoner J, Jones EA. 1986 ISIR Meeting on the Interferon System; Finland.
16. Effect of recombinant human gamma interferon therapy on immune function in patients with chronic type B hepatitis. Lisker Melman M, Ambrus J, Witzel N, Fauci AS, Park Y, Di Bisceglie AM, Hoofnagle JH. 1987 Intl Symp Viral Hep Liv Dis.
17. Alpha interferon treatment of patients with decompensated chronic hepatitis B. Kassianides C, Di Bisceglie AM, Rustgi VK, Lisker Melman M, Mullen KD, Jones DB, Peters M, Park Y, Waggoner JG, Hoofnagle JH. 1987 Intl Symp Viral Hep Liv Dis.
18. Interferon therapy of chronic viral hepatitis. Hoofnagle JH, Di Bisceglie AM. 1987 Intl Symp Viral Hep Liv Dis.
19. Inhibition of hepatitis B viral replication by recombinant human gamma interferon. Di Bisceglie AM, Rustgi VK, Kassianides C, Lisker Melman M, Waggoner JG, Park Y, Murray L, Hoofnagle JH. 1987 Intl Symp Viral Hep Liv Dis.
20. Treatment of chronic type B hepatitis with recombinant human alpha and gamma interferon in combination: a dose finding study. Di Bisceglie AM, Kassianides CK, Lisker Melman M, Rustgi VK, Murray L, Park Y, Waggoner JG, Hoofnagle JH. Hepatology 1987;7:1116.
21. Changes in lymphocyte subsets and immune function assays during treatment with gamma interferon in patients with chronic type B hepatitis. Lisker Melman M, Suou T, Ambrus J, Peters M, Paxton H, Park Y, Di Bisceglie AM, Hoofnagle JH. Hepatology 1987;7:1143.
22. Detection of HBV DNA in serum during therapy for chronic type B hepatitis using a novel highly sensitive assay. Berninger M, Di Bisceglie AM, Hoofnagle JH, Reyes A, Schuster D, Hartley J. Hepatology 1987;7:1151.
23. Development of cirrhosis following chronic non A, non B hepatitis. Di Bisceglie AM, Kassianides CK, Lisker Melman M, Waggoner JG, Martin P, Murray L, Park Y, Hoofnagle JH. Gastroenterology 1988;94:A535.
24. Changes in immune function and lymphocyte subsets in patients with chronic non A, non B hepatitis treated with recombinant human alpha interferon. Lisker Melman M, Suou T, Moreno-Otero R, Di Bisceglie AM, Murray L, Hoofnagle JH. Gastroenterology 1988;94:A564.
25. The role of hepatitis B virus infection in hepatocellular carcinoma in the United States. Di Bisceglie AM, Sjogren M, Klein J, Waggoner JG, Order S. Falk Symposium on Liver Cell Cancer 1988.
26. Absence of novel transforming DNA sequences in human hepatocellular carcinoma. Di Bisceglie AM, Dusheiko GM, Kew MC. Falk Symposium on Liver cell Cancer 1988.
27. Detection of delta virus RNA and antigen in serum of patients: utility in monitoring therapy of chronic delta hepatitis. Di Bisceglie AM, Bergmann, K, Negro F, Smedile A, Hoofnagle JH. 1988 Hepatitis B Viruses Meeting.
28. Elevation of bile acids in liver disease are more closely related to reductions in hepatic function than development of portasystemic shunts. Arns PA Di Bisceglie AM, Waggoner JG, Hoofnagle JH, Wilkinson GR, Branch RA. Hepatology 1988;8:1277.
29. Successful treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha inteferon. Lisker Melman M, Webb D, Di Bisceglie AM, Kassiandies C, Martin P, Rustgi VK, Waggoner JG, Park Y, Murray L, Hoofnagle JH. Hepatology 1988;8:1269.
30. A randomized, double blind, placebo controlled trial of alpha interferon therapy for chronic non A, non B hepatitis. Di Bisceglie AM, Kassianides C, Lisker Melman M, Martin P, Murray L, Hoofnagle JH. Hepatology 1988; 8:1222.
31. Elevated serum alanine aminotransferase activities among sexual partners and household contacts of persons with non A, non B hepatitis. Everhart JE, Di Bisceglie AM, Alter H, Kassianides C, Martin P, Lisker Melman M, Hoofnagle JH. Hepatology 1988;8:1270.
32. Non A, Non B hepatitis leads to rapidly progressive liver disease in patients with human immunodeficiency virus infection. Martin P, Di Bisceglie AM, Kassianides C, Lisker Melman M, Hoofnagle JH. Gastroenterology 1989;96:A627.
33. Factors predicting the outcome of alpha interferon therapy for chronic non A, non B hepatitis. Di Bisceglie AM, Lisker Melman M, Martin P, Kassianides C, Murray L, Hoofnagle JH. Gastroenterology 1989;96:A593.
34. Liver transplantation for hepatitis B viral infection. Lucey MR, Rosenthal S, Martin P, Di Bisceglie AM, Campbell D, Nostrant T, Appleman HD. Gastroenterology 1989;96:A624.
35. Intrahepatic markers of hepatitis delta virus infection: a study by in situ hybridization. Negro F, Bonino F, Di Bisceglie AM, Hoofnagle JH, Gerin JL. J Hepatol 1989;9:S196.
36. Assessment of HBV DNA in serum using the polymerase chain reaction: Clinical implications in chronic hepatitis B. Baker BL, Di Bisceglie AM, Miller RH, Kaneko S, Hoofnagle JH. Hepatology 1989;10:576.
37. Detection of antibody to hepatitis C virus in patients with various chronic liver diseases. Di Bisceglie AM, Alter H, Kuo G, Houghton M, Hoofnagle JH. Hepatology 1989;10:581.
38. Hepatic manifestations of chronic granulomatous disease of childhood. Korenman JC, Travis WD, Gallin JL, Melnick DA, Di Bisceglie AM. Hepatology 1989;10:655.
39. Blood borne non A, non B hepatitis (PT NANB): Immunohistochemical identification of disease and hepatitis C virus-associated antigen(s). Krawczynski K, Kuo G, Di Bisceglie AM, Houghton M, Bradley DW. Hepatology 1989;10:580.
40. Recurrence of hepatitis C after liver transplantation. Martin P, Munoz SJ, Di Bisceglie AM, Waggoner JG, Armenti V, Moritz M, Jarrell B, Maddrey WC. Gastroenterology 1990;98:A606.
41. Assessment of HBV DNA in serum using the polymerase chain reaction: Correlation with other serological and biochemical markers. Baker, Di Bisceglie AM, Waggoner JG, Miller RH, Kaneko S, Hoofnagle JH. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston.
42. Loss of hepatitis B surface antigen following treatment of chronic hepatitis B with alpha interferon. Korenman JC, Di Bisceglie AM, Baker BL, Waggoner JG, Hoofnagle JH. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston.
43. The significance of concomitant chronic hepatitis B and hepatitis C virus infection. Fong TLF, Di Bisceglie AM, Waggoner JG, Hoofnagle JH. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston.
44. Detection of hepatitis C virus RNA by the polymerase chain reaction. Cristiano K, Baker B, Di Bisceglie AM, Feinstone SM. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston.
45. Blood borne non A, non B hepatitis: Detection and identification of hepatitis C virus and disease associated antigen (HCAg) in hepatocytes. Krawczynski K, Kuo G, Houghton M, Alter M, Di Bisceglie AM, Bradley D. 1990 International Symposium on Viral Hepatitis and Liver Disease, Houston.
46. Clinical effectiveness in enzyme replacement in Gaucher's Disease. Barton NM, Brady RO, Doppelt SH, Mankin HJ, Di Bisceglie AM, Hill SC, Verederese CL, Graham OC, Argoff CE, Grewal RP, Yu K T. Clin Res 1990.
47. -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------.
48. The contribution of HCV infection to liver disease in HBsAg carriers. Lok ASF, Ma DCK, Lai CL, Di Bisceglie AM, Chung HT. Presented at the 1990 meeting of the International Association for the Study of the Liver in Gold Coast, Australia.
49. Hepatocellular HCV associated antigen and antibody: Viral specificity and relation to natural history of infection. Krawczynski K, Beach M, Di Bisceglie AM, Kim J, Alter M, Bradley D, Reyes G. Hepatology 1990;12:905.
50. Liver histopathologic changes following prolonged therapy of chronic delta hepatitis with recombinant alpha interferon. Kleiner DA, Axiotis CA, Lisker Melman M, Martin P, Kassianides C, Bergasa NV, Korenman JC, Baker BL, Raffeld M, Hoofnagle JH, Di Bisceglie AM. Hepatology 1990;12:846.
51. Ten year follow up of post transfusion non A, non B hepatitis: Histopathology and relationship to hepatitis C virus. Di Bisceglie AM, Goodman Z, Ishak KG, Hoofnagle JH, Melpolder J, Alter HJ. Hepatology 1990;12:845.
52. In chronic hepatitis B loss of serum hepatitis B viral DNA (HBV DNA) detectable by polymerase chain reaction (PCR) usually occurs at the time of loss of hepatitis B surface antigen (HBsAg). Korenman J, Baker B, Waggoner JG, Di Bisceglie AM, Hoofnagle JH. Hepatology 1990;12:845.
53. Long term treatment of duck hepatitis B virus (DHBV) infection with 2'3' dideoxyguanosine (ddG). Korenman JC, Martin P, Ford H, Nichols D, O'Brien M, Hoofnagle JH, Broder S, Di Bisceglie AM, Mitsuya H. Hepatology 1990;12:880.
54. Treatment of patients with decompensated cirrhosis due to chronic hepatitis B with recombinant human alpha interferon. Hoofnagle JH, Di Bisceglie AM, Baker, B, Korenman JC, Bergasa N, Fong TL, Waggoner JG, Park Y. Hepatology 1990;12:846.
55. High levels of serum HBV DNA and HBsAg in acute hepatitis B virus infection predict progression to chronicity. Fong TL, Di Bisceglie AM, Waggoner JG, Biswas R, Hoofnagle JH. Hepatology 1990;12:845.
56. Prevalence of anti HCV in patients with various liver diseases in Korea. Yoo JY, Shin HK, Park CK, Chung KW, Sun HS, Chung WK, Di Bisceglie AM, Waggoner JG, Hoofnagle JH. Hepatology 1990;12:975.
57. Ribavirin therapy for 6 months in patients with chronic hepatitis C. Di Bisceglie AM, Fong T-L, Fried MW, Swain MG, Bergasa NV, Shindo M, Hoofnagle JH. Gastroenterology 1991;100:A734.
58. Cytokine mRNA expression in the liver of patients with chronic hepatitis B. Shindo M, Mullin GE, Di Bisceglie AM, Fong T-L, Braun Elwert L, Hoofnagle JH, Jones EA, James SP. Gastroenterology 1991;100:A734.
59. Clinical correlations of serum HCV RNA levels in patients with chronic hepatitis C. Shindo M, Di Bisceglie AM, Cheung L, Shih JW, Hoofnagle JH. Gastroenterology 1991;100:A795.
60. Changes in hepatitis C virus RNA in serum associated with alpha interferon therapy. Shindo M, Di Bisceglie AM, Cheung L, Shih J, Baker B, Feinstone SM, Cristiano K, Hoofnagle JH. Hepatology 1990;12:884.
61. A pilot study of 2'3'dideoxyinosine (DDI) in chronic hepatitis B. Fried MW, Korenman J, Hoofnagle JH, Di Bisceglie AM, Park Y, Waggoner JG, Mitsuya H, Yarchoan R, Broder S. Gastroenterology 1991;100:A741.
62. Expression of transforming growth factor alpha (TGFa) in human hepatocellular carcinoma (HCC). Hsia CC, Axiotis CA, Di Bisceglie AM, Tabor E. Proc Am Soc Cancer Res 1991;32:51.
63. A novel non sense mutation in the pre C region of hepatitis B virus (HBV) associated with clearance of hepatitis B e antigen and progressive liver disease. Lee J-H, Zeldis JB, Baker B, Waggoner JG, Di Bisceglie AM. Hepatology 1991;14:76A.
64. Persistent hepatic HBV DNA after clearance of HBsAg from serum of patients with chronic hepatitis B. Fong T L, Di Bisceglie AM, Feinstone SM, Waggoner JG, Axiotis CA, Hoofnagle JH. Hepatology 1991;14:130A
65. Hepatitis C virus (HCV) RNA in serum and liver during acute HCV infection in chimpanzees. Shindo M, Feinstone SM, Di Bisceglie AM. Hepatology 1991;14:118A.
66. The monoethylglycinexylidide (MEGX) test of hepatic function in chronic viral hepatitis. Fried MW, Fong T L, Swain MG, Havorka R, Ruddel M, Barnett JA, Hoofnagle JH, Di Bisceglie AM, Fong EA. Hepatology 1991;14:271A.
67. Quantitation of hepatitis C virus RNA in serum using the polymerase chain reaction and a colorimetric enzymatic detection system. Shindo M, Di Bisceglie AM, Silver J, Limjoco T, Hoofnagle JH Feinstone SM. Hepatology 1991;14:64A.
68. Comparison of autoimmune (AI) and hepatitis C virus (HCV) related chronic hepatitis. Fried MW, Draguesku J, Shindo M, Simpson LH, Gracey D, Banks SM, Hoofnagle JH, Di Bisceglie AM. Hepatology 1991;14:61A.
69. Co expression of transforming growth factor alpha and hepatitis B surface antigen in the same hepatocytes of human liver tissue adjacent to hepatocellular carcinoma. Hsia CC, Axiotis CA, Di Bisceglie AM, Tabor E. Hepatology 1991;14:109A.
70. State of HBV genomes in cultured human and chimpanzee peripheral blood mononuclear cells following mitogen and cytokine treatment. Mueller C, Di Bisceglie AM, Gerin J, Korba B. Hepadnaviruses meeting. Paris, 1991.
71. HBV DNA by polymerase chain reaction in serum of patients with chronic delta hepatitis. Simpson LH, Hoofnagle JH, Di Bisceglie AM. Fourth International Symposium on Hepatitis Delta Virus and Liver Disease. Rhodes, 1992.
72. Accurate quantitation of hepatitis B virus DNA in human serum with a new rapid chemiluminescent test: Hybrid capture HBV DNA assay. Garcia M, Lazar C, Impraim C, Challberg S, Di Bisceglie AM, Lorinez A. 5th International Forum on AIDS, Hepatitis and other blood borne diseases. Atlanta, 1992.
73. Development of hepatocellular carcinoma after prolonged hepatitis C viral infection. Di Bisceglie AM, Simpson LH, Lotze MT, Hoofnagle JH. Hepatology 1992;16:530.
74. HCV RNA in liver allografts: Correlation with histopathology. Fried MW, Thung SN, Shindo M, Thiese ND, Schwartz M, Borcich T, Miller C, Di Bisceglie AM. Gastroenterology 1992;102:A808.
75. Hepatitis B virus (HBV) suppression during long term therapy with ribavirin. Fried MW, Fong T L, Swain MG, Park Y, Simpson LH, Hoofnagle JH, Di Bisceglie AM. Gastroenterology 1992;102:A808.
76. Expression of mutant p53 in human HCC from two geographic areas. Hsia CC, Axiotis CA, Di Bisceglie AM, Kleiner D, Tabor E. Proc Am Assoc Canc Res 1992:33:108.
77. Hepatitis C viral antigen (HCVAg) in liver: Effect of antiviral therapy. Di Bisceglie AM, Krawczynski K, Brazzeal D, Hoofnagle JH. Hepatology 1992;16:131A.
78. Immunohistochemical staining for RB tumor suppressor gene product: Application to human HCC. Hsia CC, Di Bisceglie AM, Tabor E. Hepatology 1992;16:57A.
79. FIAU, a new oral antiviral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B. Fried MW, Di Bisceglie AM, Straus SE, Savarese B, Beames MP, Hoofnagle JH. Hepatology 1992;16:127A.
80. A capture assay for HCV RNA using a human monospecific antibody to core antigen of HCV. Shindo M, Akatsuka T, Di Bisceglie AM, Donets M, Scaglione L, Hoofnagle JH, Feinstone SM. Hepatology 1992;16:70A.
81. Hepatic histology in apparently healthy blood donors with hepatitis C viral infection confirmed by PCR. Adania RS, Silva AEB, Di Bisceglie AM, Bordin JO, Lanzoni VP, Ferraz MLG. Hepatology 1992;16:194A.
82. HBV DNA by PCR in individuals with anti HBc as the only marker of hepatitis B virus infection. Silva AEB, McMahon BJ, Parkinson AJ, Hoofnagle JH, Di Bisceglie AM. Hepatology 1992;16:65A.
83. The effect of FIAU on chronic HBV infection in HIV infected subjects. Paar DP, Hooton TM, Smiles KA, Di Bisceglie AM, Havlir DV, Richman DD, Gretch DR, Corey L, Straus SE. ICAAC, 1992.
84. Immune mechanisms of liver damage in viral hepatitis. Di Bisceglie AM. Arch Arg Enf Ap Dig 1992;6:87 88.
85. Hepatocellular carcinoma an update. Di Bisceglie AM. Arch Arg Enf Ap Dig 1992;6:88 89.
86. Presence of HBV in peripheral blood mononuclear cells from HCV infected patients without markers of HBV infection. Korba BE, Muller C, Di Bisceglie AM, Gerin JL. 1992, Molecular Biology of Hepatitis B Viruses, University of California - San Diego.
87. Prospects for new antiviral agents in the therapy of chronic delta hepatitis. Di Bisceglie AM. 1992, Fourth International Symposium on Hepatitis Delta Virus and Liver Disease, Greece.
88. The effect of cholesterol-lowering agents on tissue and plasma cholesterol in Niemann-Pick disease, type C. Patterson MC, Higgins JJ, Abel RB, Schiffmann R, Parker CC, Argoff C, Grewal RP, Yu K, Di Bisceglie AM, Pentchev PG, Brady RO, Barton NW. 1992, AAN Scientific Program.
89. Diagnosis of chronic hepatitis C: Comparison of immunoassays and the polymerase chain reaction. Silva AE, Hosein B, Wisneiwolski R, Fang C, Shindo M, Waggoner JG, Di Bisceglie AM. Gastroenterology 1993;104:A995.
90. Hepatitis C virus recurrence by polymerase chain reaction following orthotopic liver transplantation. Kiyasu P, Di Bisceglie AM, Lovell M, Stevenson W, Pruett T, Caldwell S, McCallum R. North American Conference of GI Fellows. Tampa, FL, Feb 1993.
91. Fulminant hepatic failure in patients undergoing liver transplantation: Evidence of a non A, B, C,D,E syndrome. Ferraz MLG, Silva AEB, Campbell DA, Di Bisceglie AM, Lucey MR. Gastroenterology 1993;104:A901.
92. HCV RNA in sera of hemophiliacs with antibody to hepatitis C virus (HCV): Relationship to HIV infection and liver failure. Eyster ME, Silva AE, Di Bisceglie AM, Goedert JJ. IXth International Conference on AIDS. Berlin, 1993.
93. HCV RNA and cytokine mRNA in liver of patients with chronic hepatitis C: Effect of alpha interferon therapy. Shindo M, Hoofnagle JH, Feinstone SM, Di Bisceglie AM. 1993 International Symposium on Viral Hepatitis and Liver Disease. Tokyo.
94. Use of confirmatory tests for HCV infection in patients with hepatocellular carcinoma. Mangia A, Vallari D, Di Bisceglie AM. 1993 International Symposium on Viral Hepatitis and Liver Disease. Tokyo.
95. Hepatitis C virus recurrence after orthotopic liver transplantation: Clinical features during the 1st year. Kiyasu P, Di Bisceglie AM, Lovell M, Gaffey M, Lobo P, Ishitani M, Stevenson W, Pruett T, Caldwell S. Gastroenterology 1993;104:A928.
96. The physical state of the negative strand HCV RNA in serum. Shindo M, Di Bisceglie AM, Akatsuka T, Fong TL, Donets M, Scaglione L, Hoofnagle JH, Feinstone SM. 1993 International Symposium on Viral Hepatitis and Liver Disease. Japan.
97. Randomized, double blind placebo-controlled trial of ribavirin therapy for chronic hepatitis C. Di Bisceglie AM, Fried MW, Swain MG, Bergasa NV, Yurdaydin C, Simpson LH, Sallie R, Conjeevaram H, Kleiner D, Park Y, Hoofnagle JH. Hepatology 1993;18:93A.
98. Absence of hepatitis C viral (HCV) infection in Alaska patients with hepatocellular carcinoma (HCC) not related to hepatitis B. Chung Y-H, McMahon B, Lanier A, Parkinson AJ, Zanis C, Di Bisceglie AM. Hepatology 1993;18:82A.
99. Serum HBV DNA levels correlate with the presence of hepatic injury in patients with chronic hepatitis B seronegative for HBeAg. Mangia A, Hoofnagle JH, Di Bisceglie AM. Hepatology 1993;18:115A.
100. Long term follow up of hepatitis B virus (HBV) related glomerulonephritis treated with alpha interferon. Conjeevaram H, Balow JE, Austin H, Hoofnagle JH, Di Bisceglie AM. Hepatology 1993;18:146A.
101. Hepatitis delta virus (HDV) RNA in serum of patients with chronic delta hepatitis. Battegay M, Simpson L, Sallie R, Hoofnagle JH, Di Bisceglie AM. Hepatology 1993;18:223A.
102. Perinatal transmission of hepatitis C. DeVoid DE, Minkoff H, Goedert J, Biswas R, Di Bisceglie AM. Hepatology 1993;18:229A.
103. Ground glass hepatocytes in chronic hepatitis B: Quantitation and clinical significance. Conjeevaram HS, Kleiner DE, Hoofnagle JH, Di Bisceglie AM. Hepatology 1993;18:227A.
104. The 5' End of HCV: Characterization by end to end RNA ligation mediated polymerase chain reaction. Sallie R, Chia S-C, Hoofnagle J, Di Bisceglie AM, Feinstone SM. Hepatology 1993;18:78A.
105. Alpha-1-antitrypsin (AAT) levels and phenotypes and progression of liver disease in chronic viral hepatitis. Mahaney K, Brantly M, Redwine J, Hoofnagle JH, Di Bisceglie AM. Hepatology 1993;18:272A.
106. Genomic variability of the hepatitis C virus (HCV): Development of mutations during antiviral therapy. Mahaney K, Di Bisceglie AM, Hoofnagle JH, Sallie R. Hepatology 1993;18:92A.
107. Prevalence and significance of hepatitis C viral (HCV) infection among alcoholics without evidence of liver disease. Herion D, George DT, Eckardt MJ, Beames M, Di Bisceglie AM. Hepatology 1993;18:235A.
108. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon- . Bacon BR, Rebholz AE, Fried M, Di Bisceglie AM. Hepatology 1993;18:150A.
109. Hepatic iron concentration as a predictor of response to alpha interferon therapy in chronic hepatitis C. Olynk J, Reddy R, Di Bisceglie AM, Jeffers LJ, Parker T, Radick J, Schiff ER, Bacon BR. Hepatology 1993;18:90A.
110. Distinctive histopathological features of chronic hepatitis B in children. Kleiner DE, Conjeevaram H, Hoofnagle JH, Di Bisceglie AM. Hepatology 1993;18:118A.
111. Nalmefene therapy is associated with the relief of the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Bergasa NV, Alling DW, Talbot TL, Chia SC, Souppaya M, Conjeevaram H, Sallie R, Yurdaydin C, Wells M, Swain MG, Di Bisceglie AM, Hoofnagle JH, Jones EA. Hepatology 1993;18:177A.
112. HBV DNA detection in anti-HBe positive HBsAg carriers: comparison of a non-isotopic hybridization assay and the polymerase chain reaction. Silva AE, Mangia A, Lopez EPA, Lanzoni VP, Ferraz ML, Di Bisceglie AM. J Hepatology (for EASL), 1993.
113. --------------------------------------------------------------------------------------------------------------------------------
114. Ligase chain reaction for detection of mutation in pre-core region of HBV genome. Mangia A, Mushawar IK, Berkenmeyer L, Di Bisceglie AM. Hepatology 1994;20:307A.
115. HLA-A2 restricted cytotoxic T cells (CTL) recognize hepatitis C virus encoded NS4 and NS5 peptides strongly binding to HLA-A2. Battegay M, Akatsuka T, Di Bisceglie AM, Fikes J, Wentworth P, Ching WM, Berzofsky JA, Hoofnagle JH, Feinstone SM. 2nd International Meeting on Hepatitis C and Related Viruses. California, 1994.
116. Hepatitis C viral (HCV) markers in serum and liver of chronically infected patients. Di Bisceglie AM, Chung Y-W, Dailey PJ, Shakil AO, Krawczynski K, Hoofnagle JH. Hepatology 1994;20:236A.
117. Correlation between hepatic and serologic markers of HBV infection in patients with chronic hepatitis B. Di Bisceglie AM, Kuhns MC, McNamara A, Hoofnagle JH. Hepatology 1994;20:296A.
118. Serum levels of IgM anti-HBc in patients with chronic hepatitis B. Changes with therapy. Hayashi PH, Beames MP, Hoofnagle JH, Di Bisceglie AM. Gastroenterology 1994;106:A905.
119. A novel and rapid method of genotyping hepatitis C virus. Mahaney K, Tedeschi V, Di Bisceglie AM, Maertens G, Sallie R. Gastroenterology 1994;106:A936.
120. Liver histopathology in blood donors with hepatitis C and normal serum ALT levels. Shakil AO, Conry-Cantilena C, Melpolder J, Alter HJ, Hoofnagle JH, Krawczynski K, Tadeschi V, Di Bisceglie AM. Gastroenterology 1994;106:A981.
121. Interaction between HBV, HDV, and HCV in hemophiliacs with HIV infection. Eyster ME, Sanders JC, Di Bisceglie AM. Gastroenterology 1994;106:A889.
122. Expression of transforming growth factor alpha (TGF ) in liver of patients with chronic viral hepatitis. Chung YH, Di Bisceglie AM. Gastroenterology 1994;106:A877.
123. FIAU Toxicity: Progression lactic acidosis, hepatic failure and pancreatitis. Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Straus SE, Hoofnagle JH. 34th ICAAC. Florida, 1994.
124. Genotypic analysis of hepatitis D isolates from patients with chronic delta hepatitis in the US: Disease severity and response to interferon. Shakil AO, Casey JL, Niro GA, Di Bisceglie AM, Hoofnagle JH, Gerin JL. Hepatology 1994;20:308A.
125. Transforming growth factor- (TGF- ) in the liver before and after interferon- (IFN- ) for chronic hepatitis B. Morimitsu Y, Kleiner, Jr DE, Hsia CC, Di Bisceglie AM, Tabor E. Hepatology 1994;20:299A.
126. Ground glass hepatocytes in chronic hepatitis B: Changes with alpha interferon therapy. Conjeevaram HS, Kleiner DE, Sallie R, Marrone A, Di Bisceglie AM, Hoofnagle JH. Hepatology 1994;20:299A.
127. Serum levels of hepatitis B e antigen (HBeAg) in patients with chronic hepatitis B: changes with therapy. Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM. Gastroenterology 1995;108:A1081.
128. Analysis of hepatitis delta virus RNA and viral genotypes in patients with chronic delta hepatitis in southern Europe. Shakil AO, Casey JL, Hoofnagle JH, Di Bisceglie AM, Gerin JL, Hadziyannis S. Fifth Int'l Symposium on Hepatitis Delta Virus and Liver Disease, 1995.
129. Sequence variability of hepatitis delta virus genome: analysis of global distribution of genotypes and subtypes. Shakil AO, Casey JL, Niro GA, Hadziyannis S, Di Bisceglie AM, Hoofnagle JH, Gerin JL. Fifth Int'l Symposium of Hepatitis Delta Virus and Liver Disease, 1995.
130. Long-term therapy with ribavirin for chronic hepatitis C. Hoofnagle JH, Conjeevaram HS, Kleiner DE, Lau DT, Di Bisceglie AM. Third Int'l Meeting on Hepatitis C Virus and Related Viruses, 1995.
131. Hepatic iron concentration (HIC) in end stage liver disease (ELSD) 2o to chronic hepatitis C (HCV) and/or alcoholic liver disease (ALD). Reddy KR, Bacon BR, Tzakis A, Neuschwander-Tetri BA, Jeffers LJ, Di Bisceglie AM, Bernstein DE, Weppler D, Webb M, Nery J, de Medina M, Vioianna A, Schiff ER. Hepatology 1995;22:275A.
132. Two year course of ribavirin for chronic hepatitis C. Hoofnagle JH, Conjeevaram HS, Kleiner DE, Lau D, Di Bisceglie AM. Hepatology 1995;22:118A.
133. Autologous lymphocyte therapy (ALT) for chronic hepatitis B: A preliminary study in chimpanzees. Di Bisceglie AM, Babbitt BP, Caplan B, Bhan AK, Rall CJN, Dienstag JL. Hepatology 1995;22:329A.
134. Hepatic expression of alpha-smooth muscle actin in chronic hepatitis C: Correlation with disease activity and changes with therapy. Poulos JE, Brunt EM, Janney CG, Bacon BR, Di Bisceglie AM. Hepatology 1995;22:278A.
135. Stimulation of c-JUN kinase by fibronectin and interleukin-1 alpha is associated with increased gene expression of stromelysin in lipocytes. Poulos JE, Di Bisceglie AM, Bellezzo JM, Weber JD, Britton RS, Bacon BR, Baldassare JJ. Hepatology 1995;22:293A.
136. Antigen independent activation of T cells obtained from chronic hepatitis B patients results in enhanced responses upon restimulation by HBV antigens. Hogan C, Caplan B, Bacon B, Di Bisceglie AM, Babbitt B. Hepatology 1995;22:264A.
137. Role of hepatitis G virus in cryptogenic liver disease. Di Bisceglie AM, Bacon BR, Neuschwander-Tetri BA, Yun A, Kim JP. Gastroenterology 1996;110:A1181.
138. Fibronectin and interleukin-1 stimulate ap-1-dependent gene expression in rat hepatic stellate cells. Poulos JE, Bellezzo JM, Weber JD, Di Bisceglie AM, Britton RS, Bacon BR, Baldassare JJ. Hepatology 1996;24:459A.
139. Liver transplantation in patients with chronic hepatitis C and alcoholism. Dhar SC, Solomon H, Bacon BR, Di Bisceglie AM. Hepatology 1996;24:502A.
140. Hepatic HCV RNA in alcoholic patients undergoing liver transplantation. Fan X, Neuschwander-Tetri BA, Poulos JE, Solomon H, Di Bisceglie AM. Hepatology 1996;24:508A.
141. Ribavirin therapy for chronic hepatitis C (CHC): A dose-duration dependent improvement in inflammatory activity. Kleiner DE, Di Bisceglie AM, Hoofnagle JH. U.S. and Canadian Academy of Pathology Meeting, 1997.
142. Hepatitis C-associated cryoglobulinemia presenting as necrotizing vasculitis of the gall bladder and appendix. Ramrakhiani S, Brunt EM, Di Bisceglie AM. American College of Gastroenterology, 62nd Annual Scientific Meeting, 1997.
143. Viral hepatitis in an elderly nursing home population. Chein NT, Horani M, Morley JE, Di Bisceglie AM. JAGS 1997;45:880.
144. Positron emission tomography (PET) scanning in the diagnosis of hepatocellular carcinoma. Combs CS, Lowe VJ, Wolverson MK, Brunt EM, Collins BT, Solomon H, Di Bisceglie AM. Hepatology 1997;26:242A.
145. Iron reduction therapy in chronic hepatitis C. Di Bisceglie AM, Bonkovsky H, Krawitt E, Grace N, Killenberg P, Hunt C, Chopra S, Reddy RK, Flamm S, Tavill AS, Ferguson R, Tamburro C, Osmack P, Bacon BR. Hepatology 1977;26:151A.
146. A comparison of hepatitis C viral quasispecies in liver and serum. Fan X, Neuschwander-Tetri BA, Poulos JE, Solomon H, Di Bisceglie AM. Hepatology 1997;26:300A.
147. Is hepatitis G virus hepatotropic?: Detection of HGV RNA in serum and liver tissue of patients undergoing liver transplantation. Fan X, Solomon H, Neuschwander-Tetri B, Poulos JE, Di Bisceglie AM. Hepatology 1997;26:92.
148. A proposal for grading and staging the histopathologic findings in nonalcoholic steatohepatitis (NASH). Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Mod Pathol 1998;11:151A.
149. Comparison of 24 vs. 48 weeks of interferon and ribavirin in combination for patients with chronic hepatitis C not responding to previous therapy with interferon alone. Di Bisceglie AM, Rauscher, J, Smith-Wilkaitis N, Randall D, Koehler K, Bacon BR. US Rebetol Investigators' Meeting. Puerto Rico, 1998.
150. Expression of p-glycoprotein in human hepatocellular carcinoma and cirrhosis. Richart JM, Brunt EM, Di Bisceglie AM. AASLD Clinical Research Single Topic Conference, 1998.
151. Expression of C-MYC binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma. Fan X, Xu Y, Shah D, Solomon H, Neuschwander-Tetri B, Ray RB, Di Bisceglie AM. AASLD Clinical Research Single Topic Conference, 1998.
152. Influence of Hepatitis C virus genotype and development of hepatocellular carcinoma: A meta-analysis. Naeem M, Di Bisceglie AM. AASLD Clinical Research Single Topic Conference, 1998.
153. Effect of dietary iron loading in chimpanzees with chronic hepatitis C virus infection. Di Bisceglie AM, Bassett SE, Bacon BR, Lanford RE. Gastroenterology 1998;114:A1234.
154. Infection with hepatitis G (HGV) and hepatitis C (HCV) viruses in patients on chronic hemodialysis (HD). Bastani B, Frenchie D, Gellens M, Di Bisceglie AM. American Society of Nephrology 31st Annual Meeting, 1998.
155. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo-controlled phase II studies. Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, Carithers R, Rustgi V, Di Bisceglie AM, Balan V, Murray A, Rooney J, Jaffe HS for the Adefovir Dipivoxil HBV Study Teram. Hepatology 1998;28:317A.
156. Prevalence of immunity to hepatitis A and B in patients undergoing orthotopic liver transplantation. Ramrakhiani S, Solomon H, Varma CR, Osmack P, Bacon BR, Di Bisceglie AM. Hepatology 1998;28:345A.
157. Interferon-ribavirin combination: sustained response in non-responders to interferon alone including patients with normal aminotransferases and predictors of poor response. Bacon BR, Rauscher JA, Smith-Wilkaitis NL, Randall DC, Koehler KM, Antal MJ, Di Bisceglie AM. Hepatology 1998;28:372A.
158. Iron grading: A proposal for a histologic system that includes the pattern, location and grade of stainable iron. Brunt EM, Britting RS, Olynyk JK, Di Bisceglie AM, Bacon BR. Hepatology 1998;28:423A.
159. Clinical improvement in patients with decompensated liver disease due to hepatitis B following treatment with lamivudine. Sponseller CA, Smith-Wilkaitis N, Bacon BR, Di Bisceglie AM. Hepatology 1998;28:589A.
160. Chronic hepatitis C viral infection in patients with normal serum aminotransferases. Di Bisceglie AM. Chronic hepatitis C viral infection in patients with normal serum aminotransferases. Di Bisceglie AM. Hepatitis C: A Meeting Ground for the Generalist and the Specialist, Washington DC, 1998.
161. The hepatitis C virus: Virology and future antiviral targets. Di Bisceglie AM. Hepatitis C: A Meeting Ground for the Generalist and the Specialist, Washington DC, 1998.
162. Inhibition of VSV/HCV Pseudotype Virus Infectivity. Ray R, Di Bisceglie AM, Conley AJ, Foung SK, Hadlock KG, Meyer K. 6th International Symposium on Hepatitis C & Related Viruses. Bethesda, MD, 1999.
163. Neutralization of VSV/HCV Pseudotype Virus Infectivity. Ray R, Meyer K, Di Bisceglie AM. 18th Annual Meeting American Society For Virology. University of Massachusetts, 1999.
164. Different ratio of nonsynonymous to synonymous nucleotide substitutions (d /ds) between serum and liver-derived HCV quasispecies. Fan X, Chambers TJ, Di Bisceglie AM. 6th International Symposium on Hepatitis C & Related Viruses. Bethesda, Maryland, 1999.
165. Changes in serum lipoprotein profile with interferon therapy in chronic hepatitis C. Naeem M, Bacon BR, Britton RS, Di Bisceglie AM. Gastroenterology 1999;116:A1203.
166. Identification of liver-specific quasispecies variants of hepatitis C virus (HCV) in chronically infected patients. Fan X, Solomon H, Ramrakhiani S, Di Bisceglie AM. Gastroenterology 1999;116:A1203.
167. Semi-quantitative detection of MRNA of C-MYC and C-MYC binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma. Fan X, Xu Y, Shah D, Solomon H, Ramrakhiani S, Ray RB, Di Bisceglie AM. Gastroenterology 1999;116:A1203.
168. Can steatohepatitis (SH) coexist with other forms of chronic liver disease (CLD)? Brunt EM, Neuschwander-Tetri BA, Di Bisceglie AM, Janney CG, Bacon BR. US and Canadian Academy of Pathology, 1999.
169. Changes in reactivity over time to hepatitis C viral peptides from the hypervariable (HVRI) region. Di Bisceglie AM, Fan X. Hepatology 1999;30:361A.
170. Silent hepatitis B virus in HBsAg-seronegative hepatocellular carcinoma patients. Hsia C-C, Scudamore CH, Di Bisceglie AM, Momosaki S, Tabor E. Hepatology 1999;30:441A.
171. Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Kew MC, Klein AS, Abrams RA, Sitzmann JV, Jones L, Sharma S, Bacon BR, Di Bisceglie AM, Groopman JD. Hepatology 1999;30:279A.
172. Compartmentalization of hepatitis C virus quasispecies. Di Bisceglie AM and Fan X. Antiviral Therapy 1999;4(Suppl 4); Abstract 13.
173. Interaction of HCV E1 and E2 glyoproteins with cell surface for pseudotype virus infectivity. Ray R, Meyer K, Lagging LM, Di Bisceglie AM. 21st US-Japan Hepatitis Panel, San Antonio, Texas, January 2000.
174. Sustained virologic response to combination therapy with interferon plus ribavirin in patients with chronic HCV infection and normal serum aminotransferases. Sreenarasimhaiah V, Bacon BR, Rauscher J, Di Bisceglie AM. 10th International Symposium on Viral Hepatitis and Liver Disease: Antiviral Therapy 2000;5(suppl 1), C96.
175. Genetic characterization of hypervariable regions of hepatitis C virus genotype 2. Fan X and Di Bisceglie AM. 10th International Symposium on Viral Hepatitis and Liver Disease: Antiviral Therapy 2000;5(suppl 1), C121.
176. Adaptive evolution of the hypervariable region 1 of the hepatitis C virus (HCV) genome in a liver transplant recipient. Fan X and Di Bisceglie AM. 10th International Symposium on Viral Hepatitis and Liver Disease: Antiviral Therapy 2000;5(suppl 1), C122.
177. The coexistence of steatohepatitis with other forms of chronic liver disease in liver biopsies. Brunt EM, Cordes BG, Neuschwander-Tetri BA, Di Bisceglie AM, Janney CG, Bacon BR. Falk Symposium 2000.
178. Hepatitis C and hepatocellular carcinoma in African Americans. Di Bisceglie AM, Schwartz M, Reddy R, Martin P, Gores GJ, Hussein K, Gish RG, Van Thiel DH, Younossi ZM, Tong MJ, Hassanein TI, Balart L, Fleckenstein JF. Gastroenterology 2000;118(2):A6514.
179. Design of the HALT-C trial (hepatitis C antiviral long-term treatment to prevent cirrhosis). Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Everson GT, Lindsay KL, Gretch DR, Hoefs JC, Lee WC, Lok AS, Tralka TS, Shiffman ML, Wright EC. Gastroenterology 2000;118(2):A6515.
180. A randomized, open label, multicenter, efficacy and safety study of new combinations of antiviral therapy in chronic hepatitis C: A preliminary report. Di Bisceglie AM, Bernstein D, Rustgi V, Gitlin N, Jeffers L, Simon D, Pappas SC, Campagna J. Hepatology 2000;_______. (AASLD 2000 meeting).
181. Hepatitis C associated with cryoglobulinemia, glomerulonephritis and retinopathy. Ramrakhiani S, Salinas-Madrigal C, Di Bisceglie AM. Regional ACP Meeting 2000.
182. Rapidly progressive hepatitis C transmitted from an HCV-positive bone marrow donor. Tan D, Pincus S, Di Bisceglie AM. Regional ACP Meeting 2000.
183. Evolution of hepatitis C virus quasispecies after liver transplantation. Lyra AC, Fan X, Ramrakhiani S, Di Bisceglie AM. Digestive Disease Week, Atlanta, GA, May 2001.
184. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multi-center, prospective, randomized, controlled trial. Bacon BR, Bonkovsky HL, Banner B, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, Di Bisceglie AM. 4th Schering Hepatitis Investigators Week, Feb. 2000.
185. Hepatitis C virus genotype 4 infection in the United States: Clinical features and response to therapy. Ramrakhiani S, Bacon BR, Varma SC, Ramrakhiani S, Di Bisceglie AM. Digestive Disease Week, Atlanta, GA, May 2001.
186. Tan D, Fan X, Richart JM, Pincus SM, Di Bisceglie AM. Digestive Disease Week, Atlanta, GA, May 2001.
187. Competition and selection among different HCV strains. Fan X, Detre KM, Belle SH, Wei YL, Wiesner RH, Charlton MR, Schafer D, Zetterman RK, Lake JR, Hoofnagle JH, Everhart JE, Di Bisceglie AM. Digestive Disease Week, Atlanta, GA, May 2001.
188. Concurrence of steatohepatitis with chronic hepatitis C and other chronic liver diseases. Ramrakhiani S, Cordes B, Brunt EM, Di Bisceglie AM. Digestive Disease Week, Atlanta, GA, May 2001.
189. PEGylated (40 kda) interferon alfa-2a (PEGASYS) in new combination therapies: A report of a randomized, multicenter efficacy and safety study. Di Bisceglie AM, Bernstein DE, Rustgi VR, Gitlin N, Jeffers LJ, Dimon D, Campagna J, Pappas SC. J Hepatology 2001;34:143.
190. Ethnic differences in patients with primary biliary cirrhosis in the USA. Peters MG, Di Bisceglie AM, Flye N, Carithers R, Combes B, and The PUMPS Study Group. Hepatology 2001;_________.
191. Genetic origin of unique hepatitis C viral (HCV) HVR1 variants after liver transplantation. Fan X, Di Bisceglie AM, Lyra AC, Xu Y. Hepatology 2001;34:416A.
192. Determination of HFE mutations in the paraffin-embedded liver biopsy blocks of patients with hepatocellular carcinoma. Younossi ZM, Steedman S, Di Bisceglie A, Gramlich T, Osmack P, Younoszai A, Grosso L, Cooper J, Duncan D, Seneca R. Hepatology 2001;34:504A.
193. Lack of deterioration of bone density in primary biliary cirrhosis with active therapy despite worsening liver disease. Di Bisceglie AM, Peters M, Loyet M. Hepatology 2001;34:526A.
194. Genetic diversity of the CD81 binding regions of HCV before and after liver transplantation. Lyra AC, Fan X, Di Bisceglie AM. Hepatology 2001;34:562A.
195. Long-term durability of sustained virologic response to antiviral therapy of hepatitis C. Bacon BR, Di Bisceglie AM, Thompson JA, Koehler KM. Hepatology 2001;34:606A.
196. Lifetime alcohol and drug abuse disorders are significantly more common in HALT-C patients compared to population controls while mood disorders are less common. Fontana RJ, Kronfol Z, Wright E, Lindsay K, Seeff L, Shiffman M, Di Bisceglie A, Bonkovsky H, Everson G, Lok ASF, Lee WM, Dienstag J, Morgan T, Morshima C, Ghany M for the HALT-C Study Group. Digestive Disease Week, San Francisco, May 2002 (submitted).
197. HCV RNA and immunological responses to thymalfasin in combination with peginterferon alfa-2a in HCV non-responders: A 12-week kinetic study. Iftikar R, Di Bisceglie A, Pockros PJ, Rustgi VK, Schulman M, Martins EB. Hepatology 2002;36:360A.
198. Clonal nature of hepatitis C virus: Full length sequencing shows lack of recombination of HCV isolates from heterologous HCV positive recipient/donor pairs in liver transplantation. Fan X, Xu Y, Lang D, Detre KM, Belle SH, Wei YL, Wiesner RH, Charlton MR, Schafer D, Bass N, Roberts J, Korber BTM, Everhart JE, Di Bisceglie AM. Hepatology 2002;36:547A.
199. Derivation, origin-dating and assembly of ancestral hepatitis C virus (HCV) envelope sequences. Fan X, Di Bisceglie AM. Hepatology 2002;36:203A.
200. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Shiffman M and the HALT-C trial investigators. Hepatology 2002;36:295A.
201. Chemoprevention of hepatocellular carcinoma by Tamoxifen. Di Bisceglie AM, Osmack P, Brunt EM. Hepatology 2002;36:697A.
202. HCV RNA and immunological responses to thymalfasin in combination with peginterferon alfa-2A in HCV non-responders: A 12-week kinetic study. Iftikhar R, Di Bisceglie AM, Pockros PJ, Rustgi VK, Schulamn M, Martins EB. Hepatology 2002;36:360A.
203. Peripheral blood B cell expansion in HCV infection is not associated with activation or differentiation. Dustin LB, Ni J, Hembrador EG, Chambers TJ, Di Bisceglie AM, Dorante G, Talal AH, Jacobson IM, Rice CM. 9th International Meeting on HCV and Related Viruses, Center for the Study of Hepatitis C, Rockefeller University, 2002.
204. HCV quasispecies dynamics during combination therapy of peginterferon alfa 2A and ribavirin. Fan X, Droll DA, Xu Y, Chambers TJ, Di Bisceglie AM. Gastroenterology 2003;124:A776.
205. Gastrointestinal surgery in patients with cirrhosis. Hoffman MG, Longo WE, Bahadursingh A, Di Bisceglie AM. Gastroenterology 2003;_________.
206. The presence of severe steatosis or steatohepatitis impairs response to antiviral therapy in patients with chronic hepatitis C. Harrison SA, Brunt EM, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR. Hepatology 2003;38:626A.
207. Monitoring HCV core antigen during antiviral therapy. Di Bisceglie AM, Strinko J, Osmack P. Hepatology 2003;38:430A.
208. Early pharmacokinetics, pharmacodynamics and hepatitis C viral kinetics on treatment with pegylated interferon (IFN) alfa-2a with or without ribavirin: characterization of the null responder. Di Bisceglie AM, Osmack P, Hoffman J, Strinko J. Hepatology 2003;38:316A.
209. Serum alpha-fetoprotein (AFP) levels in patients with advanced hepatitis C-associated liver disease without hepatocellular carcinoma: results from the HALT-C trial. Di Bisceglie AM, Dienstag J, Bonkovsky H, Sterling R, Chung R, Everhart J, Wright E, for the HALT-C investigators. Hepatology 2003;38:434A.
210. Image-guided liver biopsy in the evaluation of clinically suspected HCC: Correlation of fine needle aspiration (FNA) and core biopsy (BX). Ezenekwe AM, Brunt EM, Bialecki ES, Ponder TB, Collins BT, Bieneman BK, Di Bisceglie AM. Submitted to United States and Canadian Academy of Pathology Annual Meeting (2003).
211. The presence and spectrum of varices in the absence of cirrhosis in patients with chronic hepatitis C. Sanyal AJ, Fontana R, Everhart J, Di Bisceglie AM, Wright E. Hepatology 2003;38:218A.
212. HCV-specific immune responses at baseline do not predict virologic response to antiviral therapy in advanced hepatitis C. Morishima C, Ray R, Polyak SJ, Sullivan DG, Chang M, Di Bisceglie AM, Lee WM, Bonkovsky HL, Gretch DR, Wright EC, Rothman AL, Koziel MJ, Lindsay KL. Hepatology 2003;38:263A.
213. Diabetic hepatosclerosis: perisinusoidal hepatic fibrosis without steatohepatitis among diabetics. Harrison SA, Brunt EM, Goodman ZD, Di Bisceglie AM. Hepatology 2003;38:266A.
214. Portal hypertensive gastropathy is prevalent amongst chronic hepatitis C non-responders with bridging fibrosis and early cirrhosis: results from the HALT-C trial. Fontana RJ, Sanyal AJ, Wright E, Di Bisceglie AM. Hepatology 2003;38:294A.
215. Host immune responses do not correlate with histologic injury: baseline analysis of the HALT-C trial in advanced hepatitis C disease. Rothman AL, Morishima C, Ray R, Bonkovsky HL, Di Bisceglie AM, Lee WM, Lindsay, KL, Gretch DR, Polyak SJ, Wright EC, Koziel MJ. Hepatology 2003;38:467A.
216. GP73, a resident Golgi membrane protein, appears in sera or patients with viral liver disease and hepatocellular cancer. Romano PR, Nikolaeva OV, Steel L, Fimmel CJ, Marrero J, Evans AA, Communale MA, Lok A, London WT, Di Bisceglie AM, Block TM. Hepatology 2003;38:768A.
217. Full length genome analysis of hepatitis C virus in patients with differential responses after combined therapy of pegylated interferon-alpha and ribavirin. Tan D, Yao E, Fan X, Chambers T, Tavis J, Di Bisceglie AM. Gastroenterology 2004;126:A686.
218. Antioxidant treatment does not substantially ameliorate the fall in hemoglobin in HCV patients treated with pegylated interferon alfa-2b and ribavirin. Bacon BR, Frielich BL, Siegner JM, O'Neill R, Kissinger J, Hoffmann JA, Britton RS, Di Bisceglie AM, Brass CA. Gastroenterology 2004;126:A233.
219. Genetic and biochemical evidence for action of ribavirin through the HCV RNA polymerase in vivo. Cannon NA, Metzger LM, Donlin MJ, Lyra A, Yao E, Di Bisceglie AM, Tavis JE. 11th International Symposium on hepatitis C and related viruses. Heidelberg, Germany. October 2004.
220. Full Length Sequencing Of HCV Identifies Novel Regions Of The Viral Genome Associated With Response To Antiviral Therapy. Di Bisceglie AM, Tan D, Fan X, Tavis JE, Kuiken C. 11th International Symposium on Hepatitis C and Related Viruses. Heidelberg, Germany. October 2004.
221. Development of a replicon-based shuttle vector system for phenotypic characterization of HCV patient NS5B genes towards polymerase inhibitors. Middleton T, Lim HB, Pilot-Matias T, Tripathi R, Roth A, Koev G, Ng T, Liangjun L, Pithawalla R, Chen-C-M, Kati W, Mo H, Di Bisceglie A, Molla A. 11th International Symposium on Hepatitis C and Related Viruses. Heidelberg, Germany. October 2004.
222. Interferon-gamma stimulated chemokines predict treatment outcome in patients with chronic HCV infection. Butera D, Marukian S, Jacobson IM, Di Bisceglie AM, Chambers TJ, Rice CM, Dustin LB. 11th International Symposium on Hepatitis C and Related Viruses. Heidelberg, Germany. October 2004.
223. The epidemiology and survival of patients with hepatocellular carcinoma in the United States - A preliminary report from the Liver Cancer network. Befeler AS, Marrero JA, Chari RS, Roberts L, Afdhal N, Van Thiel D, Di Bisceglie AM. Hepatology 2004;40(Suppl 1):216A.
224. Liver biopsy evaluation in work up of hepatic lesions suspicious for hepatocellular carcinoma. Bialecki A, Ezenekwe A, Brunt EM, Collins BT, Ponder TB, Bieneman BK, Di Bisceglie AM. Hepatology 2004;40(Suppl 1):312A.
225. Prevalence of insulin resistance (IR) and impact on treatment in chronic hepatitis C (CHC). Lok AS, Everhart JE, Chung RT, Padmanbhan L, Shiffman ML, Evverson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Le WM, Morgan TR, Ghany MG, Morishima C. Hepatology 2004;40(Suppl 1):314A.
226. Pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2A or alfa-2B with ribavirin in treatment naïve patients with genotype 1 chronic hepatitis C. Di Bisceglie AM, Rustgi VK, Thuluvath P, Davis M, Ghalib R, Lyons MF, Ondovik MS, Lopez-Talavera JC, Hamzeh F. Hepatology 2004;40(Suppl 1):734A.